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BIOMARKERS FOR OVARIAN CANCER

Gynecol. Oncol., 59(1): 1 1 1-6 (1995); Zhang et al., Gynecol.
Oncol., 73(1):56-61 (1999); Zhang et al., Use of Multiple
Markers to Detect Stage I Epithelial Ovarian Cancers: Neural

CROSS-REFERENCE TO RELATED CASES

NetWork Analysis Improves Performance, American Society
of Clinical Oncology (2001); Annual Meeting, Abstract) in a
longitudinal risk of cancer model (Skates et al., Cancer, 76(10

This case is related to US. Provisional Patent Application

Nos. 60/693,755, ?led on Jun. 24, 2005, and 60/785,031, ?led
on Mar. 22, 2006, the teachings of Which are incorporated

Supp):2004-10 (1995)), and in tandem With ultrasound as a

herein by reference.

second line test (Jacobs et al., Br Med. J., 306(6884):1030-34
(1993); Menon et al., British Journal ofObstetrics and Gyne

cology, 107(2): 165-69 (2000)) have shoWn promising results

FIELD OF THE INVENTION

in improving overall test speci?city, Which is critical for a

This invention relates generally to clinical diagnostics and,

disease such as ovarian cancer that has a relatively loW preva

lence.
Due to the dismal prognosis of late stage ovarian cancer, it
is the general consensus that a physician Will accept a test

in particular, to clinical diagnostics for ovarian cancer.
BACKGROUND OF THE INVENTION

Ovarian cancer is among the most lethal gynecologic

malignancies in developed countries. Annually, in the United
States alone, approximately 23,000 Women are diagnosed
With the disease and almost 14,000 Women die from it. (Jamal

20

et al., CA CancerJ. Clin., 52:23-47 (2002)). Despite progress
in cancer therapy, ovarian cancer mortality has remained vir

tually unchanged over the past tWo decades. (Id.) Given the
steep survival gradient relative to the stage at Which the dis
ease is diagnosed, early detection remains the most important
factor in improving long-term survival of ovarian cancer

87 (1998)).
25

speci?city for early detection of ovarian cancer (Bast et al.,
Early detection of ovarian cancer: promise and reality, Ova
rian Cancer: ISIS Medical Media Ltd., Oxford, UK (2001), in

The poor prognosis of ovarian cancer diagnosed at late
30

general population together pose extremely stringent require

press). Without an acceptable screening test, early detection
remains the most critical factor in improving long-term sur
vival of patients With ovarian cancer.

ments on the sensitivity and speci?city of a test for it to be

used for screening for ovarian cancer in the general popula
tion.
The identi?cation of tumor markers suitable for the early
detection and diagnosis of cancer holds great promise to

Thus, there is a critical need for neW serological markers
that individually or in combination With other markers or

diagnostic modalities deliver the required sensitivity and

patients.
stages, the cost and risk associated With con?rmatory diag
nostic procedures, and its relatively loW prevalence in the

With a minimal positive predictive value of 10%. (Bast et al.,
Cancer Treatment and Research, 107:61-97 (2002)). Extend
ing this to the general population, a general screening test
Would require a sensitivity greater than 70% and a speci?city
of 99.6%. Currently, none of the existing serologic markers,
such as CA125, CA72-4, or M-CSF, individually delivers
such a performance (Bast et al., Int. J Biol. Markers, 13: 179

Thus, it is desirable to have a reliable and accurate method
35

of determining the ovarian cancer status in patients, the
results of Which can then be used to manage subject treat
ment.

improve the clinical outcome of patients. It is especially
important for patients presenting With vague or no symptoms

SUMMARY OF THE INVENTION

or With tumors that are relatively inaccessible to physical

examination. Despite considerable effort directed at early

40

detection, no cost effective screening tests have been devel

oped (Paley, Curr Opin. Onc0l., 13(5):399402 (2001)) and
Women generally present With disseminated disease at diag
nosis. (OZols et al. Epithelial ovarian cancer. In: Hoskins W J,
PereZ C A, Young R C, editors. Principles and Practice of

nosing ovarian cancer, as Well as methods and kits for using
the biomarkers to diagnose ovarian cancer.
More speci?cally, in one aspect, the present invention pro
45

Gynecologic Oncology. 3rd ed. Philadelphia: Lippincott,

vides a method for qualifying ovarian cancer status in a sub

ject comprising: (a) measuring at least one biomarker in a
biological sample from the subject, Wherein the at least one
biomarker is selected from the group consisting of the biom
arkers of Tables 1, 3 and 4; and (b) correlating the measure

Williams and Wilkins; pages 981-1057 (2000)).
The best-characterized tumor marker, CA125, is negative
in approximately 30-40% of stage I ovarian carcinomas and
its levels are elevated in a variety of benign diseases. (Meyer

The present invention ?lls these needs by providing novel
biomarkers and combinations of biomarkers useful for diag

50

ment With ovarian cancer status. In one embodiment, the at

least one biomarker is selected from the group consisting of

et al., Br. J. Cancer, 82(9):l535-8 (2000); Buamah, J. Surg.
Oncol., 75(4):264-5 (2000); Tuxen et al., Cancer Treat. Rev.,

ApoC1, Hemoglobin alpha/beta, ApoAII, ApoCII, Calgranu

21 (3):21 5-45 (1995)). Its use as a population-based screening
tool for early detection and diagnosis of ovarian cancer is

lin C, Calgranulin C (truncated form), Calgranulin A, Calcy
clin, Transthyretin (doubly charged) and IgG heavy chain. In

hindered by its loW sensitivity and speci?city (MacDonald et
al., Eur. J. Obstet. Gynecol. Reprod. Biol., 82(2):l55-7
(1999); Jacobs et al., Hum. Repr0d., 4(1): 1 -12 (1989); Shih et
al., Tumor markers in ovarian cancer, Diamandis, Fritsche,
Lilja, Chan, and SchWartZ, editor; Tumor markers physiol
ogy, pathobiology, technology and clinical applications,
Philadelphia: AACC Press; in press). Although pelvic and

55

lin C, Calgranulin C (truncated form), Calgranulin A, Calcy
clin, Transthyretin and IgG heavy chain. In another embodi
ment, the method further comprises measuring some other
60

combination With additional tumor markers (Woolas et al., J.

National Cancer Inst, 85(21):1748-51 (1993); Woolas et al.,

knoWn biomarker for ovarian cancer, such as CA125.

In another embodiment, the method further comprises

more recently vaginal sonography has been used to screen

high-risk patients, neither technique has the su?icient sensi
tivity and speci?city to be applied to the general population
(MacDonald et al., supra). Recent efforts in using CA125 in

another embodiment, the method involves measuring each of

ApoC1, Hemoglobin alpha/beta, ApoAII, ApoCII, Calgranu

measuring some other knoWn biomarker for ovarian cancer,
such as CA125. In a further embodiment, the method further
65

comprises measuring and correlating at least one biomarker
selected from the group consisting of CA125, transferrin,

haptoglobin, ApoA1, transthyretin, ITIH4 internal fragment,
beta 2-microglobulin, hepcidin, prostatin, osteopontin, esoi

US 8,465,929 B2
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nophil-derived neurotoxin, leptin, prolactin, IGF-II, hemo

the at least one biomarker is selected from the group consist

globin and modi?ed forms thereof. In yet another embodi
ment, the method further comprises CAl25 II, CAl5-3,
CAl 9-9, CA72-4, CA 195, tumor associated trypsin inhibitor

ing of biomarkers of Tables 1, 3 and 4.
Another embodiment of the invention provides a method
for determining the course of ovarian cancer comprising (a)

(TATI), CEA, placental alkaline phosphatase (PLAP), Sialyl
TN, galactosyltransferase, macrophage colony stimulating

measuring, at a ?rst time, at least one biomarker in a biologi

cal sample from the subject, Wherein the at least one biomar
ker is selected from the group consisting of the biomarkers of
Tables 1, 3 and 4; and (b) measuring, at a second time, the at
least one biomarker in a biological sample from the subject;
and (c) comparing the ?rst measurement and the second mea
surement; Wherein the comparative measurements determine

factor (M-CSF, CSF- l ), lysophosphatidic acid (LPA), 110 kD
component of the subject. extracellular domain of the epider
mal growth factor receptor (pl IOEGFR), tissue kallikreins,
e.g., kallikrein 6 and kallikrein l0 (NES-l), prostasin, HE4,
creatine kinase B (CKB), LASA, HER-2/neu, urinary gona

the course of the ovarian cancer.

dotropin peptide, Dianon NB 70/K, Tissue peptide antigen

In yet another embodiment, the at least one biomarker is

(TPA), SMRP, osteopontin, and haptoglobin, leptin, prolac

selected from the group consisting of: ApoCl, Hemoglobin

tin, insulin-like groWth factorI and insulin-like groWth factor

alpha/beta, ApoAII, ApoCII, Calgranulin C, Calgranulin C

II. These additional biomarkers can also be measured and

(truncated form), Calgranulin A and IgG heavy chain. In a
further embodiment, the method comprises measuring each
of the folloWing biomarkers: ApoCl, Hemoglobin alpha/

correlated using the other methods, kits and softWare of the
present invention.
In one embodiment of the above method, the at least one

beta, ApoAII, ApoCII, Calgranulin C, Calgranulin C (trun

biomarker is measured by capturing the biomarker on an
adsorbent surface of a SELDI probe and detecting the cap
tured biomarkers by laser desorption-ionization mass spec
trometry. In another embodiment, the at least one biomarker
is measured by an immunoassay. This latter method is par

20

ticularly useful When the identity of the biomarker is knoWn.

25

CA125.
In still another embodiment, the at least one biomarker is

selected from the group consisting of: ApoCl, ApoAII,

In one embodiment, the sample is ovarian cyst ?uid. In a
related embodiment, the adsorbent is a member selected from
the group consisting of a hydrophobic adsorbent, an anion
exchange adsorbent, a cation exchange adsorbent and a metal

chelate adsorbent. In yet another embodiment, the adsorbent
is a cation exchange adsorbent.
In another embodiment, the biomarkers of the invention are

Calgranulin A, Calgranulin C, Calcyclin, and Transthyretin
(doubly charged). In another embodiment, the method further
30

In addition to the methods described herein, the invention

also provides compositions comprising a puri?ed biomol
ecule selected from the biomarkers of Tables 1, 3 and 4. In
35

40

of loW malignant potential, ovarian cancer (malignant) and
other malignant conditions. In one embodiment, the ovarian
45

50

comprising a biospeci?c capture reagent bound to a biomar
ker of Tables 1, 3 and 4.
In other embodiments, the invention provides kits. For
example, in one embodiment, the invention provides a kit
comprising: (a) a solid support comprising at least one cap
ture reagent attached thereto, Wherein the capture reagent

the biomarkers of Tables 1, 3 and 4; and (b) instructions for
using the solid support to detect a biomarker of Tables 1, 3 and
4. In a related embodiment, the kit further comprises instruc
tions for using the solid support to detect a biomarker selected

from the group consisting of: ApoCl, Hemoglobin alpha/

beta, ApoAII, ApoCII, Calgranulin C, Calgranulin C (trun

malignant conditions.
In another embodiment, the methods described herein of
detecting biomarkers and correlating the measurements With
ovarian cancer status further comprise managing subject

another embodiment, the invention provides a composition

binds at least one biomarker from a ?rst group consisting of

ovarian disease, ovarian cancer (malignant) and other malig
nant conditions. In yet another embodiment, the ovarian can
cer status rules out the possibility of benign ovarian disease.
In still a further embodiment, the ovarian cancer status rules
out the possibility of ovarian cancer (malignant) and other

another embodiment, the invention provides a composition
comprising a biospeci?c capture reagent, e.g., an antibody,
that speci?cally binds a biomolecule selected from the biom
arkers of Tables 1, 3 and 4. In a related embodiment, the
biospeci?c capture reagent is bound to a solid support. In yet

performed by a softWare classi?cation algorithm. Generally,

cancer status is selected from benign ovarian disease and
ovarian cancer of loW malignant potential versus ovarian
cancer (malignant) and other malignant conditions. In
another embodiment, the ovarian cancer status is selected
from ovarian cancer of loW malignant potential versus benign

comprises measuring some other knoWn biomarker for ova
rian cancer, such as CA125.

ovarian cancer status. In one embodiment, the correlating is

in the method of the present invention, the ovarian cancer
status is selected from benign ovarian disease, ovarian cancer

ApoCII, Calgranulin A, Calgranulin C, Calcyclin, and Tran
sthyretin (doubly charged). In another embodiment, the
method involves measuring each ofApoCl,ApoAII, ApoCII,

measured by a method other than mass spectrometry or meth
ods that rely on a measurement of the mass of the biomarker.

For instance, in certain embodiments, the biomarkers of this
invention are measured by immunoassay.
As indicated, the above method is directed to qualifying

cated form), Calgranulin A and IgG heavy chain. In a related

embodiment, the method comprises additionally measuring

55

cated form), Calgranulin A and IgG heavy chain. In another
embodiment, the kit comprises instructions for using the solid
support to detect each of the biomarkers: ApoCl, Hemoglo

bin alpha/beta, ApoAII, ApoCII, Calgranulin C, Calgranulin

treatment based on the status. In a related embodiment, if the

C (truncated form), CalgranulinA and I gG heavy chain. In yet

measurement correlates With ovarian cancer, then managing

another embodiment, the kits further comprise instructions
for using the solid support to detect CA125.
In still another related embodiment, the kit comprises

subject treatment comprises administering a chemotherapeu

60

tic agent to the subject. In another embodiment, the methods
further comprise measuring the at least one biomarker after
subject management and correlating the measurement With
disease progression, include determining the rates of disease

progression.
The invention also provides a method comprising measur
ing at least one biomarker in a sample from a subject, Wherein

instructions for using the solid support to detect at least one

biomarker is selected from the group consisting of: ApoCl,

ApoAII, ApoCII, Calgranulin A, Calgranulin C, Calcyclin,
65

and Transthyretin (doubly charged). In another embodiment,
the kit comprises instructions for using the solid support to

detect each of ApoCl, ApoAII, ApoCII, Calgranulin A, Cal

US 8,465,929 B2
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granulin C, Calcyclin, and Transthyretin (doubly charged). In

of: ApoCl, ApoAII, ApoCII, Calgranulin A, Calgranulin C,
Calcyclin, and Transthyretin (doubly charged). In another

another embodiment, the kit comprises instructions for using
the solid support to detect some other knoWn biomarker for

embodiment, the classi?cation algorithm classi?es the ova

ovarian cancer, such as CAl25.

rian cancer status of the sample as a function of the measure

In another related embodiment, the solid support of the kits
comprises a capture reagent is a SELDI probe, Where the
capture reagent is a hydrophobic adsorbent, an anion
exchange adsorbent, a cation exchange adsorbent and a metal
chelate adsorbent. In yet another embodiment, the kits addi
tionally comprise a container containing at least one of the
biomarkers of Tables 1, 3 and 4. In yet another embodiment,

ment of each of the biomarkers: ApoCl, ApoAII, ApoCII,

Calgranulin A, Calgranulin C, Calcyclin, and Transthyretin
(doubly charged). In another embodiment, the classi?cation
algorithm classi?es the ovarian cancer status of the sample
further as a function of the measurement of CAl25.

The present invention additionally provides a method
Which comprises detecting a biomarker of Tables 1, 3 and 4 by

the kits additionally comprise a cation exchange chromatog
raphy sorbent.

mass spectrometry or immunoassay.

In another embodiment, the invention provides a method

In another embodiment, the invention provides a kit com

comprising communicating to a subject a diagnosis relating

prising (a) a solid support comprising at least one capture
reagent attached thereto, Wherein the capture reagents bind at

to ovarian cancer status determined from the correlation of

biomarkers in a sample from the subject, Wherein the biom
arkers are selected from the group consisting of the biomar
kers of Tables 1, 3 and 4. In a related embodiment, the diag
nosis is communicated to the subject via a computer

least one biomarker selected from the group consisting of the
biomarkers of Tables 1, 3 and 4; and (b) a container contain
ing at least one of the biomarkers. In a related embodiment,
the container contains at least one biomarker selected from

20

the group consisting of: ApoCl, Hemoglobin alpha/beta,

generated medium.

ApoAII, ApoCII, Calgranulin C, Calgranulin C (truncated

In another embodiment, the present invention provides a
method for identifying a compound that interacts With a

form), Calgranulin A and IgG heavy chain. In yet another

biomarker of Tables 1, 3 and 4, Wherein the method comprises

embodiment, the container contains each of the folloWing

biomarkers: ApoCl, Hemoglobin alpha/beta, ApoAII,
ApoCII, Calgranulin C, Calgranulin C (truncated form), Cal

(a) contacting a biomarker of Tables 1, 3 and 4 With a test
25

interacts With the biomarker of Tables 1, 3 and 4.
In another embodiment, the invention provides a method
for modulating the concentration of Calgranulin C in a cell,
Wherein the method comprises contacting said cell With an

granulinA and I gG heavy chain. In a related embodiment, the
container further contains CAl25.
In still another related embodiment, the container contains
at least one biomarker selected from the group consisting of:

30

ApoCl , ApoAII, ApoCII, CalgranulinA, Calgranulin C, Cal

cyclin, and Transthyretin (doubly charged). In another
ApoCII, Calgranulin A, Calgranulin C, Calcyclin, and Tran

istering to a subject a therapeutically effective amount of an
35

tainer further contains CAl25.

In yet another embodiment, the solid support of the kits
comprises a capture reagent is a SELDI probe, Where the
capture reagent is a hydrophobic adsorbent, an anion
exchange adsorbent, a cation exchange adsorbent and a metal
chelate adsorbent. In yet another embodiment, the kits addi
tionally comprise a container containing at least one of the
biomarkers of Tables 1, 3 and 4.

inhibitor, Wherein said inhibitor prevents cleavage of Cal
granulin C.
The invention additionally provides a method of treating a
condition in a subject, Wherein saidmethod comprises admin

embodiment, the container contains each of ApoCl , ApoAII,

sthyretin (doubly charged). In another embodiment, the con

compound; and (b) determining Whether the test compound

inhibitor of Calgranulin C, Wherein the inhibitor prevents
cleavage of Calgranulin C. In a related embodiment, said
condition is ovarian cancer.

Other features, objects and advantages of the present
40

invention and its preferred embodiments Will become appar
ent from the detailed description, examples and claims that
folloW.
BRIEF DESCRIPTION OF THE DRAWINGS

The invention additionally provides a software product
comprising code that accesses data attributed to a sample, the
data comprising measurement of at least one biomarker in the

45

sample, the biomarker selected from the group consisting of
the biomarkers of Tables 1, 3 and 4; and further comprising
code that executes a classi?cation algorithm that classi?es the
ovarian cancer status of the sample as a function of the mea

FIG. 1. Representative spectra (A) and corresponding gel
vieWs (B) of cyst ?uids from individual patients With benign
(a, a'), malignant epithelial ovarian cancer (b, b'), and loW
malignant potential tumors. Fractionated by anion exchange

With descending pH (pH 9.0, 7.0, 5.0, 4.0, 3.0), then organic

surement. In a related embodiment, the softWare product

solvent, adsorbed to CMl0 ProteinChip arrays, and read at
loW laser intensity. pH 9.0 elution fractions are shoWn for

classi?es the ovarian cancer status of the sample as a function
of the measurement of a biomarker selected from the group

each patient. Representative scatter and box plots (C) shoW
variability in “peak intensity” for m/Z 10,840 (calgranulinA).

consisting of ApoCl, Hemoglobin alpha/beta, ApoAII,
ApoCII, Calgranulin C, Calgranulin C (truncated form), Cal

50

The horizontal line in each scatter plot is the mean “peak
55

granulin A and IgG heavy chain. In yet another embodiment,
the classi?cation algorithm classi?es the ovarian cancer sta
tus of the sample as a function of the measurement of each of

the biomarkers: ApoCl, Hemoglobin alpha/beta, ApoAII,
ApoCII, Calgranulin C, Calgranulin C (truncated form), Cal

intensity”. Peak m/Z 10,840 has signi?cantly greater “peak
intensity” in patients With malignant epithelial ovarian can
cer.

60

DETAILED DESCRIPTION OF THE INVENTION
AND PREFERRED EMBODIMENTS

granulin A and IgG heavy chain. In yet another embodiment,
the classi?cation algorithm classi?es the ovarian cancer sta
tus of the sample further as a function of the measurement of
CA1 25.
In a related embodiment, the softWare product classi?es the

I. Introduction

ovarian cancer status of the sample as a function of the mea

A biomarker is an organic biomolecule Which is differen
tially present in a sample taken from a subject of one pheno
typic status (e.g., having a disease) as compared With another

surement of a biomarker selected from the group consisting

phenotypic status (e.g., not having the disease). A biomarker

65

US 8,465,929 B2
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is differentially present between different phenotypic statuses

biomolecules are discriminated. In one aspect, this invention

if the mean or median expression level of the biomarker in the

provides these biomarkers in isolated form.
The biomarkers were discovered using SELDI technology

different groups is calculated to be statistically signi?cant:
Common tests for statistical signi?cance include, among oth
ers, t-test, ANOVA, Kruskal-Wallis, Wilcoxon, Mann-Whit
ney and odds ratio. Biomarkers, alone or in combination,

employing ProteinChip arrays from Ciphergen Biosystems,
Inc. (Fremont, Calif.) (“Ciphergen”). Ovarian cyst ?uid was
collected from subjects diagnosed with ovarian cancer (inva
sive epithelial ovarian cancer), ovarian cancer of low malig

provide measures of relative risk that a subject belongs to one
phenotypic status or another. Therefore, they are useful as

nant potential (borderline disease), other malignant condi

markers for disease (diagnostics), therapeutic effectiveness

tions and benign ovarian disease. A portion of the samples

of a drug (theranostics) and drug toxicity,

10 were left unfactionated and the other portion of samples were

fractionated by anion exchange chromatography. Unfraction
II. Biomarkers for Ovarian Cancer

ated and fractionated samples were applied to SELDI bio

chips and spectra of polypeptides in the samples were gener
This invention provides polypeptide-based biomarkers that
ated by time-of-?ight mass spectrometry on a Ciphergen
are differentially present in subjects having ovarian cancer, in 15 PBSII mass spectrometer. The spectra thus obtained were

particular, ovarian cancer (malignant, such as invasive epi-

analyZed by Ciphergen ExpressTM Data Manager Software

thelial ovarian cancer), ovarian cancer of low malignant

with Biomarker WiZard and Biomarker Pattern Software

potential ((LMP), borderline disease), benign ovarian disease

from Ciphergen Biosystems, Inc. The mass spectra for each

and other malignant conditions (such as malignancies other

group were subjected to scatter plot analysis. A Mann-Whit

than invasive epithelial ovarian cancer, including metastatic 20 ney test analysis was employed to compare ovarian cancer
cancer (e.g., gastric cancer metastasiZed to the ovary),
and control groups for each protein cluster in the scatter plot,
mesothelioma, a stromal ovarian cancer, etc.)). The biomarand proteins were selected that differed signi?cantly
kers are characterized by mass-to-charge ratio as determined
(p<0.000l ) between the two groups. This method is described

by mass spectrometry, by the shape of their spectral peak in

in more detail in the Example Section.

time-of-?ight mass spectrometry and by their binding char- 25
The biomarkers thus discovered are presented in Table l.
acteristics to adsorbent surfaces. These characteristics proThe “ProteinChip assay” column refers to chromatographic
vide one method to determine whether a particular detected
fraction, if applicable) in which the biomarker is found, the
biomolecule is a biomarker of this invention. These charactype of biochip to which the biomarker binds and whether the
teristics represent inherent characteristics of the biomolbiomarker is up- or down-regulated in ovarian cancer, as per
ecules and not process limitations in the manner in which the
the Example Section.
TABLE 1
Up or down

regulated in
Marker ID, m/Z

P-Value

ovarian cancer

ProteinChip ® assay

M6420/6640

<0.001

Up in

Unfractionated, H50, Q10

ApoCI
M7570/7930

<0.001

Hemoglobin

Fraction 1, CM10

Up in

Unfractionated, Q10

Malignancy

Alpha/Betal

M8690/8810

Malignancy2

<0.001

Down in LMI’3

Unfractionated, H50, Q10

<0.001

Down in LMP

Unfractionated, H50

<0.001

r/o Benign4

Unfractionated, H50, Q10

<0.001

r/o Benign

Unfractionated, H50, Q10

<0.001

r/o Malignancy4

<0.001

r/o Benign

Unfractionated, IMAC, H50
Fraction 4, IMAC30
Fraction 1, CM10, IMAC30

Down in

Fraction 1, CM10

ApoAII
M8920

ApoCII
M10210

Calcyclin
M10430
Calgranulin C
M54000
IgG heavy chain
M10840

Calgranulin A
M32600

<0.001

Malignancy6
M51000

<0.001

Down in

Fraction 3, CM10, IMAC30

Malignancy
M6880

<0.001

Transthyretin
(doubly charged)
M8660

Up in

Fraction 4, CM10

Malignancy
<0.001

Down in LMP

Fraction 4, CM10

<0.001

Up in

Fraction 4, CM10

ApoII
M75000

Malignancy
M83820

<0.001

Up in

Fraction 4, CM10

Malignancy
M94500

<0.001

Up in

Fraction 4, CM10

Malignancy
M146000

<0.001

Up in

Fraction 4, CM10

Malignancy
M4249

<0.001

Up in

Fraction 5, CM10

Malignancy
M4562

<0.001

Up in
Mali gnancy

Fraction 5, CM10

US 8,465,929 B2
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TABLE l-continued
Up or down

regulated in
Marker ID, m/z

P-Value

ovarian cancer

ProteinChip ® assay

M4630

<0.001

Up in

Fractions 4, 5, IMAC30, CM10

M6936

<0.001

Up in

Malignancy
Fraction 5, CM10

Malignancy
M63000

<0.001

Down in

Fraction 6, CM10

Malignancy
1It is noted that the hemoglobin alpha and hemoglobin beta are doubly charged in the SELDI detection assay
set forth in the Example Section
2“Up in Malignancy” means that the biomarker is up-regulated in ovarian cancer and other malignant
conditions (such as malignancies other than invasive epithelial ovarian cancer, including metastatic cancer
(e.g., gastric cancer frequently metastasizes to the ovary), mesothelioma, a stromal ovarian cancer, etc.) versus

benign ovarian disease and ovarian cancer oflow malignant potential (LMP) (borderline disease).
“Down in LMIP” means that the biomarker is down-regulated in ovarian cancer oflow malignant potential
versus the other three groups (i.e., benign ovarian disease, ovarian cancer (malignant) and other malignant

conditions).

4“r/o benign” means that the presence ofthe biomarker rules out the possibility ofbenign disease, but it is not
adequate, alone, to made a diagnosis among the other three groups (ovarian cancer LMIP, ovarian cancer

(malignant) and other malignant conditions).
“r/o Malignant” means that the presence ofthe biomarker rules out the possibility ofmalignant disease, but
is not adequate on its own to make a diagnosis of benign ovarian disease.
‘Down in Malignancy” means that the biomarker is up-regulated in ovarian cancer and other malignant

conditions versus benign ovarian disease and ovarian cancer of low malignant potential (LMP) (borderline

disease).

The identity of certain of the biomarkers of this invention
has been determined and is indicated in Table 1. The method
by which this determination was made is described in the

The biomarkers of this invention are characterized by their
mass-to-charge ratio as determined by mass spectrometry.

The mass-to-charge ratio of each biomarker is provided in
Table 1, above, Tables 2 and 3, below, after the “M.” Thus, for
example, M6420 has a measured mass-to-charge ratio of

Example Section. For biomarkers whose identify has been
determined, the presence of the biomarker can be determined

by other methods known in the art (e.g., by immunoassay).

6420. The mass-to-charge ratios were determined from mass

spectra generated on a Ciphergen Biosystems, Inc. PBS II

30

mass spectrometer. This instrument has a mass accuracy of

Because the biomarkers of this invention are characterized

by mass-to-charge ratio, binding properties and spectral

about +/—0.15 percent. Additionally, the instrument has a

shape, they can be detected by mass spectrometry without

mass resolution of about 400 to 1000 m/dm, where m is mass

knowing their speci?c identity. However, if desired, biomar

and dm is the mass spectral peak width at 0.5 peak height. The
mass-to-charge ratio of the biomarkers was determined using

kers whose identity is not determined can be identi?ed by, for

Biomarker WizardTM software (Ciphergen Biosystems, Inc.).

example, determining the amino acid sequence of the
polypeptides. For example, a biomarker can be peptide

Biomarker Wizard assigns a mass-to-charge ratio to a biom

mapped with a number of enzymes, such as trypsin or V8

arker by clustering the mass-to-charge ratios of the same
peaks from all the spectra analyzed, as determined by the
PBSII, taking the maximum and minimum mass-to-charge
ratio in the cluster, and dividing by two. Accordingly, the
masses provided re?ect these speci?cations.

35

protease, and the molecular weights of the digestion frag
ments can be used to search databases for sequences that
40

The biomarkers of this invention are further characterized

by the shape of their spectral peak in time-of-?ight mass
spectrometry.

phoresis. A band containing the biomarker is cut out and the
45

The biomarkers of this invention are further characterized

fragment is then subjected to collision-induced cooling,
which fragments the peptide and produces a polypeptide lad

this invention bind include, but are not limited to, a hydro
50

der. A polypeptide ladder is then analyzed by the second mass
spectrometer of the tandem MS. The difference in masses of

the members of the polypeptide ladder identi?es the amino
acids in the sequence. An entire protein can be sequenced this

Ciphergen® Q10 ProteinChip® array), a cation exchange
adsorbent (such as the Ciphergen® CM10 ProteinChip®
array) and a metal chelate adsorbent (such as the Ciphergen®
IMAC-30 ProteinChip® array). A number of the biomarkers
bind to a hydrophobic adsorbent (such as the Ciphergen®

protein is subject to protease digestion. Individual protein
fragments are separated by a ?rst mass spectrometer. The

by their binding properties on chromatographic surfaces.
Examples of chromatographic surfaces that the biomarkers of
phobic adsorbent (such as the Ciphergen® H50 Protein
Chip® array), an anion exchange adsorbent (such as the

match the molecular weights of the digestion fragments gen
erated by the various enzymes. Alternatively, protein biom
arkers can be sequenced using tandem MS technology. In this
method, the protein is isolated by, for example, gel electro

way, or a sequence fragment can be subjected to database
55

mining to ?nd identity candidates.

H50 ProteinChip® array) using a binding and washing buffer

The preferred biological source for detection of the biom
arkers is ovarian cyst ?uid. However, in other embodiments,

of 10% acetonitrile. Some of the biomarkers bind to an anion

the biomarkers are detected in otherbodily ?uids, e.g., serum,

exchange adsorbent (such as the Ciphergen® Q10 Protein
Chip® array) using a binding and washing buffer of 50 mM

blood or urine.
60

The biomarkers of this invention are biomolecules.

Tris buffer at pH 8.0. A number of the biomarkers bind to a

Accordingly, this invention provides these biomolecules in

metal chelate adsorbent (such as the Ciphergen® IMAC-30

isolated form. The biomarkers can be isolated from biological
?uids, such as urine or serum. They can be isolated by any
method known in the art, based on both their mass and their

ProteinChip® array coupled with copper) using, for example,
a binding and washing buffer of 50 mM Tris pH 8.0/ 500 mM
NaCl. Most of the biomarkers bind to cation exchange adsor

bents (e.g., the Ciphergen CM10 ProteinChip® array) after
washing with 100 mM sodium acetate at pH 4.

65

binding characteristics. For example, a sample comprising
the biomolecules can be subject to chromatographic fraction
ation, as described herein, and subject to further separation

US 8,465,929 B2
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by, e.g., acrylamide gel electrophoresis. Knowledge of the

betWeen various forms of the protein in a sample (e.g., certain

identity of the biomarker also alloWs their isolation by immu

immunoassays) as Well as by means that differentiate some
forms from other forms or that measure a speci?c form of the

noa?inity chromatography.

protein (e.g., mass spectrometry). In contrast, When it is
III. Biomarkers and Different Forms of a Protein

desired to measure a particular form or forms of a protein

Proteins frequently exist in a sample in a plurality of dif
ferent forms characterized by a detectably different mass.

modi?ed by truncation, phosphorylation, glycosylation, etc.),

These forms can result from either or both of pre- and post

“measuring M10430” means measuring a polypeptide having
an apparent molecular Weight of 10430 Da that, therefore,
distinguishes M10430 from other forms of Calgranulin C.

(e.g., a particular form of Calgranulin C including forms

the particular form (or forms) is speci?ed. For example,

translational modi?cation. Pre-translational modi?ed forms

include allelic variants, slice variants and RNA editing forms.
Post-translationally modi?ed forms include forms resulting
from proteolytic cleavage (e.g., fragments of a parent pro

IV. Detection of Biomarkers for Ovarian Cancer

tein), glycosylation, phosphorylation, lipidation, oxidation,
methylation, cystinylation, sulphonation and acetylation.

The biomarkers of this invention can be detected by any
suitable method. Detection paradigms that can be employed
to this end include optical methods, electrochemical methods

When detecting or measuring a protein in a sample, the ability
to differentiate betWeen different forms of a protein depends
upon the nature of the difference and the method used to
detect or measure. For example, an immunoassay using a
monoclonal antibody Will detect all forms of a protein con

20

taining the eptiope and Will not distinguish betWeen them.
HoWever, a sandWich immunoassay that uses tWo antibodies

directed against different epitopes on a protein Will detect all
forms of the protein that contain both epitopes and Will not
detect those forms that contain only one of the epitopes. In

25

diagnostic assays, the inability to distinguish different forms
of a protein has little impact When the forms detected by the
particular method used are equally good biomarkers as any
particular form. HoWever, When a particular form (or a subset
of particular forms) of a protein is a better biomarker than the
collection of different forms detected together by a particular
method, the poWer of the assay may suffer. In this case, it is
useful to employ an assay method that distinguishes betWeen
forms of a protein and that speci?cally detects and measures
a desired form or forms of the protein. Distinguishing differ
ent forms of an analyte or speci?cally detecting a particular
form of an analyte is referred to as “resolving” the analyte.

In one embodiment, a sample is analyZed by means of a
30

have a generally planar surface, to Which a capture reagent
(also called an adsorbent or af?nity reagent) is attached. Fre

quently, the surface of a biochip comprises a plurality of
addressable locations, each of Which has the capture reagent
bound there.
35
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Protein biochips are biochips adapted for the capture of
polypeptides. Many protein biochips are described in the art.

These include, for example, protein biochips produced by
Ciphergen Biosystems, Inc. (Fremont, Calif.), Zyomyx (Hay
Ward, Calif.), Invitrogen (Carlsbad, Calif.), Biacore (Upp
sala, SWeden) and Procognia (Berkshire, UK). Examples of
such proteinbiochips are described in the folloWing patents or

published patent applications: U.S. Pat. No. 6,225,047
(Hutchens et al.); U.S. Pat. No. 6,537,749 (Kuimelis et al.);
45

U.S. Pat. No. 6,329,209 (Wagner et al.); PCT International
Publication No. WO 00/56934 (Englert et al.); PCT Intema
tional Publication No. WO 03/048768 (Boutell et al.) and
Us. Pat. No. 5,242,828 (Bergstrom et al.).

Detection by Mass Spectrometry

With immunoassay. First, a biospeci?c capture reagent (e.g.,
an antibody, aptamer or A?ibody that recogniZes the biomar
ker and other forms of it) is used to capture the biomarker of

resonance spectroscopy. Illustrative of optical methods, in
addition to microscopy, both confocal and non-confocal, are
detection of ?uorescence, luminescence, chemilumines
cence, absorbance, re?ectance, transmittance, and birefrin
gence or refractive index (e.g., surface plasmon resonance,
ellipsometry, a resonant mirror method, a grating coupler
Waveguide method or interferometry).

biochip. Biochips generally comprise solid substrates and

Mass spectrometry is a particularly poWerful methodology
to resolve different forms of a protein because the different
forms typically have different masses that can be resolved by
mass spectrometry. Accordingly, if one form of a protein is a
superior biomarker for a disease than another form of the
biomarker, mass spectrometry may be able to speci?cally
detect and measure the useful form Where traditional immu
noassay fails to distinguish the forms and fails to speci?cally
detect to useful biomarker.
One useful methodology combines mass spectrometry

(voltametry and amperometry techniques), atomic force
microscopy, and radio frequency methods, e.g., multipolar

In a preferred embodiment, the biomarkers of this inven
50

tion are detected by mass spectrometry, a method that

interest. Preferably, the biospeci?c capture reagent is bound

employs a mass spectrometer to detect gas phase ions.

to a solid phase, such as a bead, a plate, a membrane or an

Examples of mass spectrometers are time-of-?ight, magnetic

array. After unbound materials are Washed aWay, the captured
analytes are detected and/ or measured by mass spectrometry.

electrostatic sector analyZer and hybrids of these.

(This method also Will also result in the capture of protein

sector, quadrupole ?lter, ion trap, ion cyclotron resonance,
55

interactors that are bound to the proteins or that are otherWise

recogniZed by antibodies and that, themselves, can be biom

on the surface of a mass spectrometry probe, a device adapted
to engage a probe interface of the mass spectrometer and to

arkers.) Various forms of mass spectrometry are useful for

detecting the protein forms, including laser desorption
approaches, such as traditional MALDI or SELDI, and elec

60

trospray ioniZation.
Thus, When reference is made herein to detecting a particu

forms of Calgranulin C by means that do not differentiate

present an analyte to ioniZing energy for ioniZation and intro
duction into a mass spectrometer. A laser desorption mass

lar protein or to measuring the amount of a particular protein,
it means detecting and measuring the protein With or Without

resolving various forms of protein. For example, the step of
“measuring Calgranulin C” includes measuring any and/or all

In a further preferred method, the mass spectrometer is a
laser desorption/ionization mass spectrometer. In laser des
orption/ioniZation mass spectrometry, the analytes are placed

65

spectrometer employs laser energy, typically from an ultra
violet laser, but also from an infrared laser, to desorb analytes
from a surface, to volatiliZe and ioniZe them and make them
available to the ion optics of the mass spectrometer. The
analysis of proteins by LDI can take the form of MALDI or of
SELDI.
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Laser desorption/ionization in a single TOF instrument
typically is performed in linear extraction mode. Tandem
mass spectrometers can employ orthogonal extraction
modes.

exchange); WCX-2, CM-10 and LWCX-30 (cation
exchange); IMAC-3, IMAC-30 and IMAC-50 (metal che
late); and PS-10, PS-20 (reactive surface With acyl-imidiZole,

epoxide) and PG-20 (protein G coupled through acyl-imidi

SELDI

Zole). Hydrophobic ProteinChip arrays have isopropyl or

A preferred mass spectrometric technique for use in the
invention is “Surface Enhanced Laser Desorption and IoniZa
tion” or“SELDI,” as described, for example, in US. Pat. Nos.
5,719,060 and 6,225,047, both to Hutchens et al. This refers
to a method of desorption/ionization gas phase ion spectrom
etry (e.g., mass spectrometry) in Which an analyte (here, one

nonylphenoxy-poly(ethylene glycol)methacrylate function

or more of the biomarkers) is captured on the surface of a
SELDI mass spectrometry probe. There are several versions
of SELDI.

carboxymethyl tyrosine functionalities (IMAC-50) that

One version of SELDI is called “a?inity capture mass

acyl-imidiZole or epoxide functional groups that can react

spectrometry.” It also is called “Surface-Enhanced Af?nity

With groups on proteins for covalent binding.
Such biochips are further described in: US. Pat. No. 6,579,

alities. Anion exchange ProteinChip arrays have quaternary
ammonium functionalities. Cation exchange ProteinChip
arrays have carboxylate functionalities. Immobilized metal
chelate ProteinChip arrays have nitrilotriacetic acid function
alities (IMAC-3 and IMAC-30) or O-methacryloyl-N,N-bis
adsorb transition metal ions, such as copper, nickel, Zinc, and

gallium, by chelation. Preactivated ProteinChip arrays have

Capture” or “SEAC.” This version involves the use of probes
that have a material on the probe surface that captures ana

719 (Hutchens et al., “Retentate Chromatography,” Jun. 17,

lytes through a non-covalent a?inity interaction (adsorption)
betWeen the material and the analyte. The material is vari
ously called an “adsorbent,” a “capture reagent,” an “a?inity
reagent” or a “binding moiety.” Such probes can be referred to
as “a?inity capture probes” and as having an “adsorbent
surface.” The capture reagent can be any material capable of
binding an analyte. The capture reagent is attached to the

2003); US. Pat. No. 6,897,072 (Rich et al. “Probes for a Gas
20

Patent Publication No. US. 2003 0032043 A1 (Pohl et al.
25

probe surface by physisorption or chemisorption. In certain
embodiments the probes have the capture reagent already

phobic Surface Chip,” May 15, 2003); US. Patent Publica
gels,” Apr. 14, 2003) and US. Pat. No. 7,045,366 (Huang et
30

a covalent or coordinate covalent bond. Epoxide and acyl
imidiZole are useful reactive moieties to covalently bind
polypeptide capture reagents such as antibodies or cellular
35

strate is Washed to remove unbound material. Any suitable

are employed. The extent to Which molecules remain bound

can be manipulated by adjusting the stringency of the Wash.

“Chromatographic adsorbent” refers to an adsorbent mate
40

acid), immobiliZed metal chelates, hydrophobic interaction

adsorbents, hydrophilic interaction adsorbents, dyes, simple
45

herein), an energy absorbing molecule then is applied to the
substrate With the bound biomarkers.

50

In yet another method, one can capture the biomarkers With
a solid-phase bound immuno-adsorbent that has antibodies
that bind the biomarkers. After Washing the adsorbent to
remove unbound material, the biomarkers are eluted from the
solid phase, applied to a SELDI biochip that binds the biom

“Biospeci?c adsorbent” refers to an adsorbent comprising
a biomolecule, e.g., a nucleic acid molecule (e.g., an
aptamer), a polypeptide, a polysaccharide, a lipid, a steroid or
a conjugate of these (e.g., a glycoprotein, a lipoprotein, a

arkers and analyZed by SELDI.

glycolipid, a nucleic acid (e.g., DNA)-protein conjugate). In

The biomarkers bound to the substrates are detected in a

55

gas phase ion spectrometer such as a time-of-?ight mass
spectrometer. The biomarkers are ioniZed by an ioniZation
source such as a laser, the generated ions are collected by an

60

ion optic assembly, and then a mass analyZer disperses and
analyZes the passing ions. The detector then translates infor
mation of the detected ions into mass-to-charge ratios. Detec
tion of a biomarker typically Will involve detection of signal
intensity. Thus, both the quantity and mass of the biomarker

certain instances, the biospeci?c adsorbent can be a macro
molecular structure such as a multiprotein complex, a bio

logical membrane or a virus. Examples of biospeci?c adsor
bents are antibodies, receptor proteins and nucleic acids.

Biospeci?c adsorbents typically have higher speci?city for a
target analyte than chromatographic adsorbents. Further
examples of adsorbents foruse in SELDI can be found in US.
Pat. No. 6,225,047. A “bioselective adsorbent” refers to an
adsorbent that binds to an analyte With an a?inity of at least

The elution characteristics of a Wash solution can depend, for

example, on pH, ionic strength, hydrophobicity, degree of
chaotropism, detergent strength, and temperature. Unless the
probe has both SEAC and SEND properties (as described

metal chelators (e.g., nitrilotriacetic acid or iminodiacetic

biomolecules (e.g., nucleotides, amino acids, simple sugars
and fatty acids) and mixed mode adsorbents (e.g., hydropho
bic attraction/ electrostatic repulsion adsorbents).

In general, a probe With an adsorbent surface is contacted
With the sample for a period of time suf?cient to alloW the
biomarker or biomarkers that may be present in the sample to
bind to the adsorbent. After an incubation period, the sub

Washing solutions can be used; preferably, aqueous solutions

matographic adsorbents and biospeci?c adsorbents.

rial typically used in chromatography. Chromatographic
adsorbents include, for example, ion exchange materials,

al., “Photocrosslinked Hydrogel Surface Coatings,” May 16,
2006.

receptors. Nitrilotriacetic acid and iminodiacetic acid are use

ful reactive moieties that function as chelating agents to bind
metal ions that interact non-covalently With histidine contain
ing peptides. Adsorbents are generally classi?ed as chro

“Latex Based Adsorbent Chip,” Jul. 16, 2002); PCT Intema
tional Publication No. WO 03/040700 (Urn et al., “Hydro
tion No. US 2003/0218130 A1 (Boschetti et al., “Biochips
With Surfaces Coated With Polysaccharide-Based Hydro

attached to the surface. In other embodiments, the probes are

pre-activated and include a reactive moiety that is capable of
binding the capture reagent, e.g., through a reaction forming

Phase Ion Spectrometer,” May 24, 2005); US. Pat. No. 6,555,
813 (Beecher et al., “Sample Holder With Hydrophobic Coat
ing for Gas Phase Mass Spectrometer,” Apr. 29, 2003); US.

can be determined.

10-8 M.

SEND

Protein biochips produced by Ciphergen Biosystems, Inc.

Another method of laser desorption mass spectrometry is

comprise surfaces having chromatographic or biospeci?c

called Surface-Enhanced Neat Desorption (“SEND”). SEND
involves the use of probes comprising energy absorbing mol
ecules that are chemically bound to the probe surface (“SEND

adsorbents attached thereto at addressable locations. Cipher

gen’s ProteinChip® arrays include NP20 (hydrophilic); 114
and H50 (hydrophobic); SAX-2, Q-10 and LSAX-30 (anion

65

probe”). The phrase “energy absorbing molecules” (EAM)
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denotes molecules that are capable of absorbing energy from
a laser desorption/ionization source and, thereafter, contrib
ute to desorption and ionization of analyte molecules in con
tact therewith. The EAM category includes molecules used in
MALDI, frequently referred to as “matrix,” and is exempli

?ed by cinnamic acid derivatives, sinapinic acid (SPA),
cyano-hydroxy-cinnamic acid (CHCA) and dihydroxyben

arkers on an immuno-chromatographic resin that comprises
antibodies that bind the biomarkers, Wash the resin to remove
unbound material, elute the biomarkers from the resin and
detect the eluted biomarkers by MALDI or by SELDI.
Other Forms of IoniZation in Mass Spectrometry
In another method, the biomarkers are detected by LC-MS
or LC-LC-MS. This involves resolving the proteins in a

Zoic acid, ferulic acid, and hydroxyaceto-phenone deriva
tives. In certain embodiments, the energy absorbing molecule

sample by one or tWo passes through liquid chromatography,
folloWed by mass spectrometry analysis, typically electro

is incorporated into a linear or cross-linked polymer, e.g., a

spray ioniZation.

polymethacrylate. For example, the composition can be a

Data Analysis
Analysis of analytes by time-of-?ight mass spectrometry

co-polymer of ot-cyano-4-methacryloyloxycinnamic acid

generates a time-of-?ight spectrum. The time-of-?ight spec
trum ultimately analyZed typically does not represent the
signal from a single pulse of ioniZing energy against a sample,

and acrylate. In another embodiment, the composition is a

co-polymer of 0t-cyano-4-methacryloyloxycinnamic acid,
acrylate and 3-(triethoxy)silyl propyl methacrylate. In

but rather the sum of signals from a number of pulses. This
reduces noise and increases dynamic range. This time-of

another embodiment, the composition is a co-polymer of

ot-cyano-4-methacryloyloxycinnamic acid and octadecyl
methacrylate (“C18 SEND”). SEND is further described in

?ight data is then subject to data processing. In Ciphergen’s

ProteinChip® softWare, data processing typically includes

US. Pat. No. 6,124,137 and PCT International Publication

No. WO 03/64594 (KitagaWa, “Monomers And Polymers

20

Having Energy Absorbing Moieties of Use In Desorption/
IoniZation Of Analytes,” Aug. 7, 2003).

frequency noise ?ltering to reduce high frequency noise.
Data generated by desorption and detection of biomarkers

SEAC/ SEND is a version of SELDI in Which both a capture
reagent and an energy absorbing molecule are attached to the

sample presenting surface. SEAC/ SEND probes therefore
alloW the capture of analytes through a?inity capture and

can be analyZed With the use of a programmable digital com
25

puter. The computer program analyZes the data to indicate the
number of biomarkers detected, and optionally the strength of
the signal and the determined molecular mass for each biom
arker detected. Data analysis can include steps of determining

30

from a predetermined statistical distribution. For example,

ionization/desorption Without the need to apply external
matrix. The C18 SEND biochip is a version of SEAC/ SEND,
comprising a C18 moiety Which functions as a capture
reagent, and a CHCA moiety Which functions as an energy

signal strength of a biomarker and removing data deviating

absorbing moiety.
SEPAR
Another version of LDI is called Surface-Enhanced Pho
tolabile Attachment and Release (“SEPAR”). SEPAR
involves the use of probes having moieties attached to the
surface that can covalently bind an analyte, and then release

TOF-to-M/Z transformation to generate a mass spectrum,

baseline subtraction to eliminate instrument offsets and high

the observed peaks can be normaliZed, by calculating the
height of each peak relative to some reference.
35

The computer can transform the resulting data into various
formats for display. The standard spectrum can be displayed,
but in one useful format only the peak height and mass infor
mation are retained from the spectrum vieW, yielding a

the analyte through breaking a photolabile bond in the moiety

cleaner image and enabling biomarkers With nearly identical

after exposure to light, e.g., to laser light (see, US. Pat. No.
5,719,060). SEPAR and other forms of SELDI are readily
adapted to detecting a biomarker or biomarker pro?le, pursu

molecular Weights to be more easily seen. In another useful
format, tWo or more spectra are compared, conveniently high
lighting unique biomarkers and biomarkers that are up- or

ant to the present invention.
MALDI
MALDI is a traditional method of laser desorption/ioniza
tionused to analyte biomolecules such as proteins and nucleic
acids. In one MALDI method, the sample is mixed With
matrix and deposited directly on a MALDI array. HoWever,

40

doWn-regulated betWeen samples. Using any of these for
mats, one can readily determine Whether a particular biom

arker is present in a sample.
45

selection can be done visually, but softWare is available, as

part of Ciphergen’ s ProteinChip® softWare package, that can
automate the detection of peaks. In general, this softWare

the complexity of biological samples such as serum and urine
makes this method less than optimal Without prior fraction

ation of the sample. Accordingly, in certain embodiments
With biomarkers are preferably ?rst captured With biospeci?c
(e. g., an antibody) or chromatographic materials coupled to a
solid support such as a resin (e.g., in a spin column). Speci?c
a?inity materials that bind the biomarkers of this invention
are described above. After puri?cation on the a?inity mate
rial, the biomarkers are eluted and then detected by MALDI.
In another mass spectrometry method, the biomarkers are
?rst captured on a chromatographic resin having chromato

functions by identifying signals having a signal-to-noise ratio
50

in some selected percentage of the mass spectra. One version

of this softWare clusters all peaks appearing in the various
55

graphic properties that bind the biomarkers. In the present
60

exchange resin, such as CM Ceramic HyperD F resin, Wash
the resin, elute the biomarkers and detect by MALDI. Alter

natively, this method could be preceded by fractionating the
sample on an anion exchange resin before application to the
cation exchange resin. In another alternative, one could frac
tionate on an anion exchange resin and detect by MALDI
directly. In yet another method, one could capture the biom

above a selected threshold and labeling the mass of the peak
at the centroid of the peak signal. In one useful application,

many spectra are compared to identify identical peaks present

example, this could include a variety of methods. For
example, one could capture the biomarkers on a cation

Analysis generally involves the identi?cation of peaks in
the spectrum that represent signal from an analyte. Peak

65

spectra Within a de?ned mass range, and assigns a mass (M/Z)
to all the peaks that are near the mid-point of the mass (M/Z)
cluster.
SoftWare used to analyZe the data can include code that

applies an algorithm to the analysis of the signal to determine
Whether the signal represents a peak in a signal that corre
sponds to a biomarker according to the present invention. The
softWare also can subject the data regarding observed biom
arker peaks to classi?cation tree or ANN analysis, to deter
mine Whether a biomarker peak or combination of biomarker

peaks is present that indicates the status of the particular
clinical parameter under examination. Analysis of the data
may be “keyed” to a variety of parameters that are obtained,

US 8,465,929 B2
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either directly or indirectly, from the mass spectrometric
analysis of the sample. These parameters include, but are not

lated from samples based on their binding characteristics.
Alternatively, if the amino acid sequence of a polypeptide
biomarker is knoWn, the polypeptide can be synthesiZed and
used to generate antibodies by methods Well knoWn in the art.

limited to, the presence or absence of one or more peaks, the

shape of a peak or group of peaks, the height of one or more

peaks, the log of the height of one or more peaks, and other

This invention contemplates traditional immunoassays

arithmetic manipulations of peak height data.

including, for example, sandWich immunoassays including

General Protocol for SELDI Detection of Biomarkers for
Ovarian Cancer

ELISA or ?uorescence-based immunoassays, as Well as other

enZyme immunoassays. Nephelometry is an assay done in
liquid phase, in Which antibodies are in solution. Binding of

A preferred protocol for the detection of the biomarkers of
this invention is as folloWs. In another embodiment, the bio

the antigen to the antibody results in changes in absorbance,

logical sample to be tested, e.g., ovarian cyst ?uid, preferably
is subject to pre-fractionation before SELDI analysis. The
prefractionation step often simpli?es the sample and
improves sensitivity. A preferred method of pre-fractionation

Which is measured. In the SELDI-based immunoassay, a bio

speci?c capture reagent for the biomarker is attached to the
surface of an MS probe, such as a pre-activated ProteinChip
array. The biomarker is then speci?cally captured on the

involves contacting the sample With an anion exchange chro

biochip through this reagent, and the captured biomarker is

matographic material, such as Q HyperD (BioSepra, SA).

detected by mass spectrometry.

The bound materials are then subject to stepWise pH elution

using buffers at pH 9, pH 7, pH 5 and pH 4. (The fractions in
Which the biomarkers are eluted also are indicated in Table 1).
Various fractions containing the biomarker are collected. In

V. Determination of Subject Ovarian Cancer Status
20

another embodiment, the biological sample to be tested, e.g.,

The biomarkers of the invention can be used in diagnostic

ovarian cyst ?uid samples, is not subject to a pre-fractionation
step, but is used in the chip binding step unfractionated.
The sample to be tested (either unfractionated or pre-frac
tionated) is then contacted With an a?inity capture probe.

tests to assess ovarian cancer status in a subject, e.g., to

25

Examples of a?inity capture probes of chromatographic sur
faces that the biomarkers of this invention bind include, but
are not limited to, a hydrophobic adsorbent (such as the

Ciphergen® H50 ProteinChip® array), an anion exchange
adsorbent (such as the Ciphergen® Q10 ProteinChip®

tions), the risk of developing disease, the stage of the disease,
30

array), a cation exchange adsorbent (such as the Ciphergen®
CMl0 ProteinChip® array) and a metal chelate adsorbent
(such as the Ciphergen® IMAC-30 ProteinChip® array). The
probe is Washed With a buffer that Will retain the biomarker
While Washing aWay unbound molecules. A suitable Wash for
each biomarker is the buffer identi?ed in the Example Sec
tion. The biomarkers are detected by laser desorption/ioniza

may be indicated, including additional diagnostic tests or
35
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analyte.

The correlation of test results With ovarian cancer status

applying a classi?cation algorithm of some kind to the results
to generate the status. The classi?cation algorithm may be as
simple as determining Whether or not the amount of a given
biomarker measured is above or beloW a particular cut-off
number. When multiple biomarkers are used, the classi?ca
tion algorithm may be a linear regression formula. Altema

tively, the classi?cation algorithm may be the product of any
of a number of learning algorithms described herein.

Alternatively, if antibodies that recogniZe the biomarker
are available, for example in the case of Apolipoprotein Cl

(ApoCl), hemoglobin alpha, hemoglobin beta, Apolipopro

the progress of disease (e.g., progress of disease or remission
of disease over time) and the effectiveness or response to
treatment of disease. Based on this status, further procedures

therapeutic procedures or regimens.

tion mass spectrometry.

Alternatively, samples may be diluted, With or Without
denaturing, in the appropriate array binding buffer and bound
and Washed under conditions optimiZed for detecting each

diagnose ovarian cancer. The phrase “ovarian cancer status”
includes any distinguishable manifestation of the disease. For
example, ovarian cancer disease status includes, Without limi
tation, the presence or absence of disease (e.g., ovarian cancer
(malignant) versus ovarian cancer of loW malignant potential
versus benign ovarian disease versus other malignant condi

45

teinAII (ApoAII), Apolipoprotein CII (ApoCII), Calgranulin
C (both full-length and truncated form), Calgranulin A, IgG

In the case of complex classi?cation algorithms, it may be
necessary to perform the algorithm on the data, thereby deter
mining the classi?cation, using a computer, e.g., a program
mable digital computer. In either case, one can then record the

heavy chain, Calcyclin and Transthyretin, these can be

status on tangible medium, for example, in computer-read

attached to the surface of a probe, such as a pre-activated

able format such as a memory drive or disk or simply printed
on paper. The result also could be reported on a computer

PSl0 or PS20 ProteinChip array (Ciphergen Biosystems,

50

Inc.). These antibodies can capture the biomarkers from a
sample onto the probe surface. Then the biomarkers can be
detected by, e. g., laser desorption/ionization mass spectrom

screen.

Single Markers
The poWer of a diagnostic test to correctly predict status is
commonly measured as the sensitivity of the assay, the speci

etry.
Any robot that performs ?uidics operations can be used in
these assays, for example, those available from HeWlett Pack
ard and Hamilton.

55

Detection by Immunoassay
In another embodiment of the invention, the biomarkers of
the invention are measured by a method other than mass
spectrometry or methods that rely on a measurement of the

mass of the biomarker. In another embodiment, the biomar
kers of this invention are measured by immunoassay. Immu
noassay requires biospeci?c capture reagents, such as anti
bodies, to capture the biomarkers. Antibodies can be

produced by methods Well knoWn in the art, e.g., by immu
niZing animals With the biomarkers. Biomarkers can be iso

?city of the assay or the area under a receiver operated char

acteristic (“ROC”) curve. Sensitivity is the percentage of true
positives that are predicted by a test to be positive, While
speci?city is the percentage of true negatives that are pre
dicted by a test to be negative. An ROC curve provides the
60
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sensitivity of a test as a function of l-speci?city. The greater
the area under the ROC curve, the more poWerful the predic
tive value of the test. Other useful measures of the utility of a

test are positive predictive value and negative predictive
value. Positive predictive value is the percentage of people
Who test positive that are actually positive. Negative predic
tive value is the percentage of people Who test negative that
are actually negative.

US 8,465,929 B2
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The biomarkers of this invention show a statistical differ
ence in different ovarian cancer statuses of at least p§0.05,

tivity and speci?city of at least 75%, at least 80%, at least
85%, at least 90%, at least 95%, at least 98% and about 100%.
Each biomarker listed in Tables 1, 3 and 4 is differentially
present in ovarian cancer (malignant), in ovarian cancer LMP,
in benign ovarian disease or in other malignant conditions),

and/or speci?city of the test. A combination of at least tWo
biomarkers is sometimes referred to as a “biomarker pro?le”
or “biomarker ?ngerprint.” A combination of the biomarkers
set forth in Tables 1, 3 and 4 can be detected. Similarly, one or
more of the biomarkers set forth in Tables 1, 3 and 4 can be
detected in combination With other knoWn ovarian cancer
biomarkers, such as CAl25. Examples of knoWn ovarian
cancer biomarkers useful in combination With the biomarkers
of the present invention include, but are not limited to, those
set forth in PCT Publications Nos. WO 03/057014 and WO

p§l0_2, p§l0_3, p210-4 or p§l0_5. Diagnostic tests that
use these biomarkers alone or in combination shoW a sensi

and, therefore, each is individually useful in aiding in the

2004/012588, both of Which are incorporated herein by ref

determination of ovarian cancer status. The method involves,

erence for all purposes.

?rst, measuring the selected biomarker in a subject sample

The protocols described in the Examples beloW Were used
to generate mass spectra from 65 patient samples, 30 of Which

using the methods described herein, e.g., capture on a SELDI

biochip folloWed by detection by mass spectrometry and,

Were diagnosed With ovarian cancer and 35 of Which did not
exhibit ovarian cancer. The peak masses and heights Were
abstracted into a discovery data set. This data set Was used to

second, comparing the measurement With a diagnostic
amount or cut-off that distinguishes a positive ovarian cancer
status from a negative ovarian cancer status. The diagnostic
amount represents a measured amount of a biomarker above
Which or beloW Which a subject is classi?ed as having a

particular ovarian cancer status. For example, if the biomar
ker is up-regulated compared to normal during ovarian can

train a learning algorithm employing classi?cation and

regression tree analysis (CART) (Ciphergen Biomarker Pat
20

or near best decision tree to classify a sample as ovarian

cancer (malignant), ovarian cancer LMP, benign ovarian dis
ease or other malignant condition. Among the many decision

cer, then a measured amount above the diagnostic cutoff

provides a diagnosis of ovarian cancer. Alternatively, if the
biomarker is doWn-regulated during ovarian cancer, then a
measured amount beloW the diagnostic cutoff provides a
diagnosis of ovarian cancer. As is Well understood in the art,

25

one can increase sensitivity or speci?city of the diagnostic
30

cut-off to suit the diagnostician’s desired levels of speci?city

35

sions, depends on the details of the assay used to generate the

rithm from, for example, a neW sample set or a different assay

protocol, the operator uses a protocol that detects these biom

arkers and keys the learning algorithm to include them.

Combinations of Markers
While individual biomarkers are useful diagnostic biom
arkers, it has been found that a combination of biomarkers can

provide greater predictive value of a particular status than
single biomarkers alone. Speci?cally, the detection of a plu
rality of biomarkers in a sample can increase the sensitivity

particular the cut-off values used in making branching deci
discovery data set. The data acquisition parameters of the
assay that produced the data used in the present analysis is
provided in the Example. In developing a classi?cation algo

ent ovarian cancer statuses, as Was done here, and draWing the

and sensitivity.

trees generated by CART, several had excellent sensitivity
and speci?city in distinguishing ovarian cancer (malignant,
such as invasive epithelial ovarian cancer) from ovarian can
cer of loW malignant potential versus benign ovarian disease.
It is also noted that the speci?cs of the decision trees, in

by adjusting the particular diagnostic cut-off used in an assay,
assay depending on the preference of the diagnostician. The
particular diagnostic cut-off can be determined, for example,
by measuring the amount of the biomarker in a statistically
signi?cant number of samples from subjects With the differ

terns SoftWareTM). lnparticular, CART chose many subsets of
the peaks at random. For each subset, CART generated a best

Also, a diagnostic test for ovarian cancer status involving
the measurement of any biomarker of this invention in com
40

bination With any of the folloWing biomarkers for ovarian
cancer identi?ed in Table 2 (including their modi?ed forms

Where appropriate):
TABLE 2

Marker

Comments (up- or down-regulated in cancer)

CTAP3

Up-regulated; 9293D

Transferrin

IMAC-Cu 100 mM Na phosphate, pH 7.0
Down-regulated; 79 kD, detected on IMAC

Haptoglobin precursor protein fragment

WO 03/057014
Up-regulated; 9.2 kD detected on IMAC

ProteinChip array charged With nickel

ProteinChip array charged With nickel
WO 03/057014

ApoAl

Down-regulated; predicted mass 28078.62D;
detected on IMAC or H50 ProteinChip array.

WO 2004/013609

Transthyretin and transthyretin delta N 10

Down-regulated; predicted mass l376lD and
12887 D, respectively; detected on Q10

ProteinChip array.
WO 2004/013609

ITIH4 intemal fragments

Up-regulated; among other fragments:

MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF
(SEQ ID NO: 1), a fragment spanning amino
acids 660-689 of human Inter-alpha trypsin
inhibitor, heavy chain H4, predicted mass:
3273.72 D; detected on IMAC ProteinChip array
WO 2004/013609 and WO 2005/098447

US 8,465,929 B2
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TABLE 2-continued
Marker

Comments (up- or down-regulated in cancer)

Beta 2-micro globulin

Up-regulated; detected at 11.7 KD on IMAC-Cu

ProteinChip array
US Provisional Application No. 60/693,679, ?led
Jun. 24, 2005
Hepcidin and modi?ed forms

Up-regulated; detected by SELDI - co

precipitate with ITIH4 fragment.
Hepcidin-25 (SEQ ID NO: 2):
DTHFPICIFCCGCCHRSKCGMCCKT

Hepcidin-24 (SEQ ID NO: 3):
THFPICIFCCGCCHRSKCGMCCKT

Hepcidin-22 (SEQ ID NO: 3):
FPICIFCCGCCHRSKCGM CCKT

Hepcidin-20 (SEQ ID NO: 4):
ICIFCCGCCHRSKCGMCCKT

Haptoglobin alpha

Up-regulated. Detected at 11,600D-11,700D on
an IMAC ProteinChip array charged with
copper;
WO 02/100242

Pro statin

Up-regulated

Osteop ontin

Up-regulated

US. Pat. No. 6,846,642
In urine - Glycosylated -- US 2005-0009120 A1
In serum - US 2005-0214826

Eosinophil-derived neurotoXin

Up regulated in urine. Glycosylated Detected at
17.4 KDa on a WCX2 ProteinChip array.
US 2005-0009120 A1

leptin

Down-regulated;
US 2005-0214826

prolactin

Up-regulated;
US 2005-0214826

IGF-II

Down-regulated;
US 2005-0214826

Hemoglobin (alpha-hemoglobin, beta-

Up-regulated;

hemoglobin)
CA 125

WO 2006-019906
Up-regulated

Other biomarkers with which the biomarkers of the present

35

arker amounts or patterns are characteristic of various risk

CTAP3, CA125 II, CA15-3, CA19-9, CA72-4, CA 195,
tumor associated trypsin inhibitor (TATI), CEA, placental

states, e.g., high, medium or low. The risk of developing a
disease is determined by measuring the relevant biomarker or
biomarkers and then either submitting them to a classi?cation

alkaline phosphatase (PLAP), Sialyl TN, galactosyltrans
ferase, macrophage colony stimulating factor (M-CSF, CSF

pattern of biomarkers that is associated with the particular
risk level.

invention can be combined include, but are not limited to,

algorithm or comparing them with a reference amount and/or
40

1), lysophosphatidic acid (LPA), 110 kD component of the
extracellular domain of the epidermal growth factor receptor

Determining Stage of Disease
In one embodiment, this invention provides methods for
determining the stage of disease in a subject. Each stage of the

(p110EGFR), tissue kallikreins, e.g., kallikrein 6 and kal

likrein 10 (NES-l), prostasin, HE4, creatine kinase B (CKB),

LASA, HER-2/neu, urinary gonadotropin peptide, Dianon
NB 70/ K, Tissue peptide antigen (TPA), SMRP, osteopontin,

disease has a characteristic amount of a biomarker or relative
45

disease is determined by measuring the relevant biomarker or

and haptoglobin, leptin, prolactin, insulin like growth factor I

biomarkers and then either submitting them to a classi?cation
algorithm or comparing them with a reference amount and/or

or II.

Ovarian Cancer Status
Determining ovarian cancer status typically involves clas

amounts of a set of biomarkers (a pattern). The stage of a

50

pattern of biomarkers that is associated with the particular
stage. For example, one can classify between early stage

sifying an individual into one of two or more groups (statuses)

ovarian cancer and non-ovarian cancer or among stage I ova

based on the results of the diagnostic test. The diagnostic tests
described herein can be used to classify between a number of

rian cancer, stage II ovarian cancer and stage III ovarian

different states.

Determining Course (Progression/Remission) of Disease

Presence of Ovarian Cancer
In one embodiment, this invention provides methods for
determining the presence of ovarian cancer in a subject (sta

cancer.

55

In one embodiment, this invention provides methods for
determining the course of disease in a subject. Disease course

refers to changes in disease status over time, including dis

tus: ovarian cancer versus ovarian cancer of low malignant

ease progression (worsening) and disease regression (im

potential or benign ovarian disease). The presence or absence
of ovarian cancer is determined by measuring the relevant

provement). Over time, the amounts or relative amounts (e.g.,
60

biomarker or biomarkers and then either submitting them to a
classi?cation algorithm or comparing them with a reference

these markers, either increased or decreased over time toward
diseased or non-diseased indicates the course of the disease.
Accordingly, this method involves measuring one or more
biomarkers in a subject at least two different time points, e.g.,

amount and/or pattern of biomarkers that is associated with

the particular risk level.
Determining Risk of Developing Disease
In one embodiment, this invention provides methods for
determining the risk of developing disease in a subject. Biom

the pattern) of the biomarkers changes. Therefore, the trend of

65

a ?rst time and a second time, and comparing the change in
amounts, if any. The course of disease is determined based on

these comparisons.

US 8,465,929 B2
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Similarly, changes in the rate of disease progression (or

physician. Alternatively, the diagnosis may be sent to a test

regression) may be monitored by measuring the amount of a

subject by email or communicated to the subject by phone. A
computer may be used to communicate the diagnosis by

biomarker, e. g., a peptide biomarkers of Table l, at different

times and calculating the rate of change in biomarker levels.

email or phone. In certain embodiments, the message con

The ability to measure disease state or velocity of disease

taining results of a diagnostic test may be generated and
delivered automatically to the subject using a combination of
computer hardWare and softWare Which Will be familiar to
artisans skilled in telecommunications. One example of a
healthcare-oriented communications system is described in
US. Pat. No. 6,283,761; hoWever, the present invention is not
limited to methods Which utiliZe this particular communica
tions system. In certain embodiments of the methods of the
invention, all or some of the method steps, including the

progression can be important for drug treatment studies
Where the goal is to sloW doWn or arrest disease progression

through therapy.
Reporting the Status
Additional embodiments of the invention relate to the com
munication of assay results or diagnoses or both to techni

cians, physicians or patients, for example. In certain embodi
ments, computers Will be used to communicate assay results
or diagnoses or both to interested parties, e.g., physicians and
their patients. In some embodiments, the assays Will be per
formed or the assay results analyZed in a country or jurisdic
tion Which differs from the country or jurisdiction to Which

assaying of samples, diagnosing of diseases, and communi
cating of assay results or diagnoses, may be carried out in

diverse (e.g., foreign) jurisdictions.
VI. Determining Therapeutic Ef?cacy of
Pharmaceutical Drug

the results or diagnoses are communicated.

In a preferred embodiment of the invention, a diagnosis
based on the differential presence in a test subject of any of the
peptide biomarkers of Tables 1, 3 or 4 is communicated to the
subject as soon as possible after the diagnosis is obtained. The

20

In another embodiment, this invention provides methods
for determining the therapeutic ef?cacy of a pharmaceutical

diagnosis may be communicated to the subject by the sub

drug. These methods are useful in performing clinical trials of

ject’s treating physician. Alternatively, the diagnosis may be

the drug, as Well as monitoring the progress of a patient on the

sent to a test subject by email or communicated to the subject

25

by phone. A computer may be used to communicate the
diagnosis by email or phone. In certain embodiments, the
message containing results of a diagnostic test may be gen
erated and delivered automatically to the subject using a
combination of computer hardWare and softWare Which Will
be familiar to artisans skilled in telecommunications. One

doctor or clinical researcher monitors the effect of the drug on
the patient or subject over the course of administration. If the
30

drug has a pharmacological impact on the condition, the
amounts or relative amounts (e. g., the pattern or pro?le) of the
biomarkers of this invention changes toWard a non-disease

example of a healthcare-oriented communications system is
described in US. Pat. No. 6,283,761; hoWever, the present
invention is not limited to methods Which utiliZe this particu
lar communications system. In certain embodiments of the
methods of the invention, all or some of the method steps,

drug. Therapy or clinical trials involve administering the drug
in a particular regimen. The regimen may involve a single
dose of the drug or multiple doses of the drug over time. The

pro?le. For example, biomarkers ApoCI and hemoglobin are
increased With disease, While biomarker M32600 is
35

decreased in disease. Therefore, one can folloW the course of

the amounts of these biomarkers in the subject during the

including the assaying of samples, diagnosing of diseases,

course of treatment. Accordingly, this method involves mea

and communicating of assay results or diagnoses, may be

suring one or more biomarkers in a subject receiving drug

carried out in diverse (e.g., foreign) jurisdictions.

therapy, and correlating the amounts of the biomarkers With
the disease status of the subject. One embodiment of this
method involves determining the levels of the biomarkers at at
least tWo different time points during a course of drug therapy,
e.g., a ?rst time and a second time, and comparing the change
in amounts of the biomarkers, if any. For example, the biom

Subject Management

40

In certain embodiments of the methods of qualifying ova

rian cancer status, the methods further comprise managing
subject treatment based on the status. Such management

includes the actions of the physician or clinician subsequent
to determining ovarian cancer status. For example, if a phy

45

sician makes a diagnosis of ovarian cancer, then a certain

regime of treatment, such as prescription or administration of

arkers can be measured before and after drug administration
or at tWo different time points during drug administration.
The effect of therapy is determined based on these compari

an anti-chemotherapeutic agent might folloW. Alternatively, a

sons. If a treatment is effective, then the biomarkers Will trend

diagnosis of ovarian cancer LMP or benign ovarian disease

toWard normal, While if treatment is ineffective, the biomar

might be folloWed With further testing to determine a speci?c

50

disease that might the patient might be suffering from. Also,
if the diagnostic test gives an inconclusive result on ovarian
cancer status, further tests may be called for.
Additional embodiments of the invention relate to the com
munication of assay results or diagnoses or both to techni

effective, then the biomarkers Will trend toWard normal, While
if treatment is ineffective, the biomarkers Will trend toWard
disease indications.
55

cians, physicians or patients, for example. In certain embodi
ments, computers Will be used to communicate assay results
or diagnoses or both to interested parties, e.g., physicians and
their patients. In some embodiments, the assays Will be per
formed or the assay results analyZed in a country or jurisdic
tion Which differs from the country or jurisdiction to Which

60

the results or diagnoses are communicated.

In a preferred embodiment of the invention, a diagnosis
based on the presence or absence in a test subject of any the
biomarkers of Table l is communicated to the subject as soon

kers Will trend toWard disease indications. If a treatment is
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VII. Generation of Classi?cation Algorithms for
Qualifying Ovarian Cancer Status
In some embodiments, data derived from the spectra (e. g.,
mass spectra or time-of-?ight spectra) that are generated
using samples such as “knoWn samples” can then be used to
“train” a classi?cation model. A “knoWn sample” is a sample
that has been pre-classi?ed. The data that are derived from the
spectra and are used to form the classi?cation model can be
referred to as a “training data set.” Once trained, the classi?
cation model can recogniZe patterns in data derived from

as possible after the diagnosis is obtained. The diagnosis may

spectra generated using unknoWn samples. The classi?cation

be communicated to the subject by the subject’s treating

model can then be used to classify the unknoWn samples into

US 8,465,929 B2
25

26

classes. This canbe useful, for example, in predicting Whether

Data”), and US. Patent Application No. 2003 0055615 A1

or not a particular biological sample is associated With a

(Zhang et al., “Systems and Methods for Processing Biologi

certain biological condition (e.g., diseased versus non-dis

cal Expression Data”).
The classi?cation models can be formed on and used on

eased).
The training data set that is used to form the classi?cation

any suitable digital computer. Suitable digital computers

model may comprise raW data or pre-processed data. In some
embodiments, raW data can be obtained directly from time

include micro, mini, or large computers using any standard or

of-?ight spectra or mass spectra, and then may be optionally
“pre-processed” as described above.
Classi?cation models can be formed using any suitable

LinuxTM based operating system. The digital computer that is

specialiZed operating system, such as a Unix, WindoWsTM or

used may be physically separate from the mass spectrometer
that is used to create the spectra of interest, or it may be
coupled to the mass spectrometer.
The training data set and the classi?cation models accord
ing to embodiments of the invention can be embodied by
computer code that is executed or used by a digital computer.

statistical classi?cation (or “leaming”) method that attempts
to segregate bodies of data into classes based on objective
parameters present in the data. Classi?cation methods may be

either supervised or unsupervised. Examples of supervised

The computer code can be stored on any suitable computer

and unsupervised classi?cation processes are described in

readable media including optical or magnetic disks, sticks,

Jain, “Statistical Pattern Recognition: A Review,” IEEE

tapes, etc., and can be Written in any suitable computer pro

Transactions on Pattern Analysis and Machine Intelligence,
Vol. 22, No. 1, January 2000, the teachings of Which are

incorporated by reference.
In supervised classi?cation, training data containing

gramming language including C, C++, visual basic, etc.
20

The learning algorithms described above are useful both
for developing classi?cation algorithms for the biomarkers

examples of knoWn categories are presented to a learning

already discovered, or for ?nding neW biomarkers for ovarian
cancer. The classi?cation algorithms, in turn, form the base

mechanism, Which learns one or more sets of relationships

for diagnostic tests by providing diagnostic values (e.g., cut
off points) for biomarkers used singly or in combination.

that de?ne each of the knoWn classes. NeW data may then be

applied to the learning mechanism, Which then classi?es the
neW data using the learned relationships. Examples of super
vised classi?cation processes include linear regression pro

cesses (e.g., multiple linear regression (MLR), partial least
squares (PLS) regression and principal components regres
sion (PCR)), binary decision trees (e. g., recursive partitioning

25

VIII. Use of Biomarkers for Imaging
Non-invasive medical imaging techniques such as Positron
Emisson Tomography (PET) or single photon emission com
30

netWorks, discriminant analyses (e.g., Bayesian classi?er or
Fischer analysis), logistic classi?ers, and support vector clas
si?ers (support vector machines).

brain disease. PET and SPECT imaging shoWs the chemical
functioning of organs and tissues, While other imaging tech
35

brain diseases such as AlZheimer’s disease. In some

instances, the use of PET or SPECT imaging alloWs AlZhe
imer’s disease to be detected several years earlier than the
40

2002/0138208 A1 to Paulse et al., “Method for AnalyZing

Mass Spectra.”
In other embodiments, the classi?cation models that are

created can be formed using unsupervised learning methods.
Unsupervised classi?cation attempts to learn classi?cations
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based on similarities in the training data set, Without pre
classifying the spectra from Which the training data set Was

derived. Unsupervised learning methods include cluster
analyses. A cluster analysis attempts to divide the data into

niquesisuch as X-ray, CT and MRIiShOW structure. The
use of PET and SPECT imaging has become increasingly

useful for qualifying and monitoring the development of

A preferred supervised classi?cation method is a recursive
partitioning process. Recursive partitioning processes use
recursive partitioning trees to classify spectra derived from

unknoWn samples. Further details about recursive partition
ing processes are provided in US. Patent Application No.

puteriZed tomography (SPECT) imaging are particularly use
ful for the detection of cancer, coronary artery disease and

processes such as CARTiclassi?cation and regression
trees), arti?cial neural netWorks such as back propagation

onset of symptoms. See, e. g.,Vassaux and Groot-Wassink, “In
Vivo Noninvasive Imaging for Gene Therapy,” J. Biomedi
cine and Biotechnology, 2: 92-101 (2003).
Different strategies are being used to develop compounds
suitable for in vivo imaging of amyloid deposits in human
brains. Monoclonal antibodies against A-beta and peptide
fragments have had limited uptake by the brain When tested in
patients With AD. The small molecular approach for amyloid
imaging has so far been most successful, as described by, e. g.,

Nordberg A, Lancet Neurol., 3(9):519-27 (2004); Kung MP
50

et al, Brain Res., 1025(1-2):98-105 (2004); HerholZ K et al.,

“clusters” or groups that ideally should have members that are
very similar to each other, and very dissimilar to members of

Mol Imaging Biol., 6(4):239-69 (2004); Neuropsychol Rev.,

other clusters. Similarity is then measured using some dis

Med., 17(2):79-89 (2003).

tance metric, Which measures the distance betWeen data
items, and clusters together data items that are closer to each

ZakZanis K K et al., 13(1): 1 -1 8 (2003); HerholZ K, Ann Nucl

The peptide biomarkers disclosed herein, or fragments
55

thereof, can be used in the context of PET and SPECT imag

other. Clustering techniques include the MacQueen’s

ing applications. After modi?cation With appropriate tracer

K-means algorithm and the Kohonen’ s Self-Organizing Map

residues for PET or SPECT applications, peptide biomarkers
Which interact With amyloid plaque proteins can be used to

algorithm.

image the deposition of amyloid plaques in AlZheimer’s

Learning algorithms asserted for use in classifying biologi
cal information are described, for example, in PCT Interna
tional Publication No. WO 01/31580 (Barnhill et al., “Meth

60

Antisense technology may be used to detect expression of
transcripts Whose translation is correlated With the biomark

ods and Devices for Identifying Patterns in Biological
Systems and Methods of Use Thereof”), US. Patent Appli

ers identi?ed herein. For example, the use of antisense pep

cation No. 2002 0193950 A1 (Gavin et al., “Method or ana

lyZing mass spectra”), US. Patent Application No. 2003
0004402 A1 (Hitt et al., “Process for Discriminating BetWeen
Biological States Based on Hidden Patterns from Biological

patients.
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tide nucleic acid (PNA) labeled With an appropriate radionu
clide, such as 11 1In, and conjugated to a brain drug-targeting
system to enable transport across biologic membrane barri
ers, has been demonstrated to alloW imaging of endogenous
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gene expression in brain cancer. See Suzuki et al., Journal of
Nuclear Medicine, 10: 1766-1775 (2004). Suzuki et al. utilize
a delivery system comprising monoclonal antibodies that tar

reagents, the kit can comprise a solid support With a reactive

surface, and a container comprising the biospeci?c capture

reagent.
The kit can also comprise a Washing solution or instruc

get transferring receptors at the blood-brain barrier and facili

tions for making a Washing solution, in Which the combina
tion of the capture reagent and the Washing solution alloWs

tate transport of the PNA across that barrier.

IX. Compositions of Matter

capture of the biomarker or biomarkers on the solid support

for subsequent detection by, e.g., mass spectrometry. The kit
may include more than type of adsorbent, each present on a

In another aspect, this invention provides compositions of

different solid support.

matter based on the biomarkers of this invention.

In a further embodiment, such a kit can comprise instruc

In one embodiment, this invention provides biomarkers of
this invention in puri?ed form. Puri?ed biomarkers have util
ity as antigens to raise antibodies. Puri?ed biomarkers also
have utility as standards in assay procedures. As used herein,

tions for suitable operational parameters in the form of a label
or separate insert. For example, the instructions may inform a
consumer about hoW to collect the sample, hoW to Wash the
probe or the particular biomarkers to be detected.
In yet another embodiment, the kit can comprise one or

a “puri?ed biomarker” is a biomarker that has been isolated

from other proteins and peptides, and/ or other material from
the biological sample in Which the biomarker is found. Biom
arkers may be puri?ed using any method knoWn in the art,

including, but not limited to, mechanical separation (e.g.,

more containers With biomarker samples, to be used as stan

dard(s) for calibration.
XI. Use of Biomarkers for Ovarian Cancer in

20

centrifugation), ammonium sulphate precipitation, dialysis

Screening Assays and Methods of Treating Ovarian

(including size-exclusion dialysis), size-exclusion chroma

Cancer

tography, a?inity chromatography, anion-exchange chroma
to graphy, cation-exchange chromatography, and methal-che
late chromatography. Such methods may be performed at any

The methods of the present invention have other applica
25

screen for compounds that modulate the expression of the
biomarkers in vitro or in vivo, Which compounds in turn may
be useful in treating or preventing ovarian cancer in patients.
In another example, the biomarkers can be used to monitor the

appropriate scale, for example, in a chromatography column,
or on a biochip.

In another embodiment, this invention provides a biospe

ci?c capture reagent, optionally in puri?ed form, that speci?
cally binds a biomarker of this invention. In one embodiment,

tions as Well. For example, the biomarkers can be used to

30

response to treatments for ovarian cancer. In yet another

the biospeci?c capture reagent is an antibody. Such compo

example, the biomarkers can be used in heredity studies to

sitions are useful for detecting the biomarker in a detection

determine if the subject is at risk for developing ovarian

assay, e.g., for diagnostics.
In another embodiment, this invention provides an article
comprising a biospeci?c capture reagent that binds a biom

cancer.

Thus, for example, the kits of this invention could include
35

a solid substrate having a hydrophobic function, such as a

arker of this invention, Wherein the reagent is bound to a solid

protein biochip (e.g., a Ciphergen H50 ProteinChip array,

phase. For example, this invention contemplates a device
comprising bead, chip, membrane, monolith or microtiter
plate derivatized With the biospeci?c capture reagent. Such

e.g., ProteinChip array) and a sodium acetate buffer for Wash
ing the substrate, as Well as instructions providing a protocol

articles are useful in biomarker detection assays.

40

Compounds suitable for therapeutic testing may be
screened initially by identifying compounds Which interact

In another aspect this invention provides a composition
comprising a biospeci?c capture reagent, such as an antibody,
bound to a biomarker of this invention, the composition

With one or more biomarkers listed in Tables 1, 3 and 4. By

Way of example, screening might include recombinantly

optionally being in puri?ed form. Such compositions are
useful for purifying the biomarker or in assays for detecting
the biomarker.
In another embodiment, this invention provides an article
comprising a solid substrate to Which is attached an adsor
bent, e. g., a chromatographic adsorbent or a biospeci?c cap
ture reagent, to Which is further bound a biomarker of this
invention. In one embodiment, the article is a biochip or a

45

cally in aqueous conditions, and interactions betWeen the test
compound and the biomarker are measured, for example, by
50

measuring elution rates as a function of salt concentration.
Certain proteins may recognize and cleave one or more biom

arkers of Tables 1, 3 and 4, in Which case the proteins may be
detected by monitoring the digestion of one or more biomar

kers in a standard assay, e.g., by gel electrophoresis of the
55

X. Kits for Detection of Biomarkers for Ovarian
Cancer

proteins.
In a related embodiment, the ability of a test compound to
inhibit the activity of one or more of the biomarkers of Tables

1, 3 and 4 may be measured. One of skill in the art Will
recognize that the techniques used to measure the activity of

In another aspect, the present invention provides kits for
60

a particular biomarker Will vary depending on the function

and properties of the biomarker. For example, an enzymatic
activity of a biomarker may be assayed provided that an
appropriate substrate is available and provided that the con

the kit comprises a solid support, such as a chip, a microtiter
plate or a bead or resin having a capture reagent attached

thereon, Wherein the capture reagent binds a biomarker of the
invention. Thus, for example, the kits of the present invention
can comprise mass spectrometry probes for SELDI, such as
ProteinChip® arrays. In the case of biospeci?c capture

expressing a biomarker listed in Tables 1, 3 or 4, purifying the
biomarker, and af?xing the biomarker to a substrate. Test

compounds Would then be contacted With the substrate, typi

probe for mass spectrometry, e.g., a SELDI probe. Such
articles are useful for purifying the biomarker or detecting the
biomarker.

qualifying ovarian cancer status, Which kits are used to detect
biomarkers according to the invention. In one embodiment,

to measure the biomarkers of this invention on the chip and to
use these measurements to diagnose ovarian cancer.

centration of the substrate or the appearance of the reaction
65

product is readily measurable. The ability of potentially
therapeutic test compounds to inhibit or enhance the activity
of a given biomarker may be determined by measuring the
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rates of catalysis in the presence or absence of the test com

arkers listed in Tables 1, 3 and 4 may be measured directly by
Western blot using radio- or ?uorescently-labeled antibodies
Which speci?cally bind to the biomarkers. Alternatively,

pounds. The ability of a test compound to interfere With a

non-enZymatic (e. g., structural) function or activity of one of
the biomarkers of Tables 1, 3 and 4 may also be measured. For

changes in the levels of mRNA encoding the one or more
biomarkers may be measured and correlated With the admin
istration of a given test compound to a subject. In a further
embodiment, the changes in the level of expression of one or
more of the biomarkers may be measured using in vitro meth
ods and materials. For example, human tissue cultured cells

example, the self-assembly of a multi-protein complex Which
includes one of the biomarkers of Tables 1, 3 and 4 may be
monitored by spectroscopy in the presence or absence of a test

compound. Alternatively, if the biomarker is a non-enZymatic
enhancer of transcription, test compounds Which interfere
With the ability of the biomarker to enhance transcription may
be identi?ed by measuring the levels of biomarker-dependent

Which express, or are capable of expressing, one or more of

transcription in vivo or in vitro in the presence and absence of

the biomarkers of Tables 1, 3 and 4 may be contacted With test
compounds. Subjects Who have been treated With test com

the test compound.

pounds Will be routinely examined for any physiological

Test compounds capable of modulating the activity of any

effects Which may result from the treatment. In particular, the
test compounds Will be evaluated for their ability to decrease

of the biomarkers of Tables 1, 3 and 4 may be administered to
patients Who are suffering from or are at risk of developing

disease likelihood in a subject. Alternatively, if the test com

ovarian cancer or other cancer. For example, the administra

pounds are administered to subjects Who have previously
been diagnosed With ovarian cancer, test compounds Will be
screened for their ability to sloW or stop the progression of the

tion of a test compound Which increases the activity of a
particular biomarker may decrease the risk of ovarian cancer

in a patient if the activity of the particular biomarker in vivo
prevents the accumulation of proteins for ovarian cancer.
Conversely, the administration of a test compound Which
decreases the activity of a particular biomarker may decrease
the risk of ovarian cancer in a patient if the increased activity
of the biomarker is responsible, at least in part, for the onset

20

disease.

XII. Examples
Example 1
25

Discovery of Biomarkers for Ovarian Cancer

of ovarian cancer.

In an additional aspect, the invention provides a method for

identifying compounds useful for the treatment of disorders

Samples:

such as ovarian cancer Which are associated With increased

Ovarian cyst ?uid samples Were acquired from the Univer

one embodiment, cell extracts or expression libraries may be

sity of Kentucky. The samples had been collected from
patients intra-operatively and stored at —80° C. Sample dis

screened for compounds Which catalyze the cleavage of full

tribution Was as follows: invasive epithelial ovarian cancer

length Calgranulin C (M10430) to truncated forms of Cal

(OvCa), 12; loW malignant potential (borderline), 13; other
malignancies, 6; and benign, 39.
Samples: Serum Pro?ling:

levels of modi?ed forms of Calgranulin C. For example, in

30

granulin C (M10210). In one embodiment of such a screening

assay, cleavage of Calgranulin C may be detected by attach
ing a ?uorophore to Calgranulin C Which remains quenched
When Calgranulin C is uncleaved, but Which ?uoresces When
the protein is cleaved. Alternatively, a version of full-length
Calgranulin C modi?ed so as to render the amide bond
betWeen amino acids x and y uncleavable may be used to

35

Ovarian cyst pro?ling Was performed using both direct
chip binding procedures as Well as anion exchange fraction
40

selectively bind or “trap” the cellular protesase Which cleaves
full-length Calgranulin C at that site in vivo. Methods for
screening and identifying proteases and their targets are Well
documented in the scienti?c literature, e.g., in LopeZ-Ottin et

al. (Nature Reviews, 3:509-519 (2002)).

Were thaWed on ice, added to a 96 Well-plate (folloWing the

template for arrangement), and centrifuged for 20 minutes at
4000 rpm. Aliquots of the cyst ?uid Were then put into fresh
96 Well-plates and stored at —80° C. until use. Serum samples
45

Arrays. All replicates Were prepared on the same day and
Were read on a PCS4000. Arrays Were processed With sample
using a Biomek 2000 or Tecan Aquarius robot.

of a disease, e. g., ovarian cancer, Which is associated With the

increased levels of truncated Calgranulin C. For example,
50

full-length Calgranulin C, combinatorial libraries may be
screened for compounds Which inhibit the cleavage activity
of the identi?ed proteins. Methods of screening chemical
pounds may be intelligently designed based on the structure
of Calgranulin C.
At the clinical level, screening a test compound includes
obtaining samples from test subjects before and after the
subjects have been exposed to a test compound. The levels in

1. 5 ul sample Was denatured With 7.5 ul U9 buffer.

3. Added 112.5 pl 50 mM tris, pH9 buffer to make ?nal
volume as 125 pl.
55

the art. For example, the levels of one or more of the biom

4. 5 ul of this denature sample Was applied to all four chip

types.

Chip Binding:
60

the samples of one or more of the biomarkers listed in Tables

1, 3 and 4 may be measured and analyZed to determine
Whether the levels of the biomarkers change after exposure to
a test compound. The samples may be analyZed by mass
spectrometry, as described herein, or the samples may be
analyZed by any appropriate means knoWn to one of skill in

Direct Chip Binding Protocol:
2. Shake at 40 C. for 20 minutes.

libraries for such compounds are Well-knoWn in art. See, e.g.,

LopeZ-Otin et al. (2002). Alternatively, inhibitory com

Were pro?led on IMAC-Cu++ on Oct. 6, 2004 and on Q10 on

Oct. 14, 2004 (see, protocol beloW) on triplicate ProteinChip

In yet another embodiment, the invention provides a
method for treating or reducing the progression or likelihood

after one or more proteins have been identi?ed Which cleave

ation folloWed by chip binding procedures. Randomized tem
plates containing the samples to be pro?led Were generated
using the Ciphergen Express softWare program. Samples

65

IMAC30: IMAC30 ProteinChip arrays Were coupled With
copper. The binding and Washing buffer Was 50 mM Tris
pH 8.0/500 mM NaCl.
CM10: The binding and Washing buffer Was 100 mM
NaAcetate pH 4.0.
H50: The binding and Washing buffer Was 10% acetonitrile
buffer.
Q10: The binding and Washing buffer Was 50 mM tris
buffer at pH8.0.
Binding time: 60 minutes at room temperature.
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Matrix Was Sinapinic Acid.

1. Anion Exchange Fractionation Protocol:
Buffer List:

U9 (9 M urea, 2% CHAPS, 50 mM Tris-HCl pH9).
.
.
.
.

U1 (1 M urea, 0.22% CHAPS, 50 mM Tris-HCl pH9).
50 mM Tris-HCl With 0.1% OGP pH9 (Wash buffer 1).
50 mM Hepes With 0.1% OGP pH7 (Wash buffer 2).
100 mM NaAcetate With 0.1% OGP pH5 (Wash buffer

3).
6. 100 mM NaAcetate With 0.1% OGP pH4 (Wash buffer

4).
7. 50 mM NaCitrate With 0.1% OGP pH3 (Wash buffer 5).
8. 33.3% isopropanol/l 6.7% acetonitrile/0. 1% tri?uorace

tic acid (Wash buffer 6).
Note: Do not aliquot Wash buffer 6 into the buffer tray until
Wash buffer 5 is being applied to the resin. This ensures
that evaporation of the volatile organic solvents Will not
be an issue.

Material List:

20

Filter plate.
6 v-Well 96 Well dishes, labeled Fl-F6.
A. Wash Resin

Prepare resin by Washing Hyper Q DF resin 3 times With 5
bed volumes 50 mM Tris-HCl pH9. Then store in 50 mM
Tris-HCl pH9 in a 50% suspension.
B. Denature Serum Protein
ThaW frozen serum and spin 20000 g for 10' at 4°.
Aliquot 20 pl serum to each Well of the 96-Well plate.

25

Add 30 pl U9 to each sample.

30

Vortex 20' at 4°.

C. Equilibrate Resin
Add 180 pl (240 pl for rat serum) Hyper Q DF to each Well
in ?lter plate.
Filter buffer.
Add 200 pl Ul to each Well.
Filter buffer.
Add 200 pl Ul to each Well.
Filter buffer.
Add 200 pl Ul to each Well.
Filter buffer.
D. Bind Serum With Resin

Pipet 50 pl of sample from each Well to corresponding Well
in ?lter plate.
Add 50 pl of U1 to each Well of sample plate.

35

Vortex 10' at Room Temperature (RT).
Collect remainder of fraction 2 in plate F2.
Fraction 2 contains the pH 7 eluant.
Add 100 pl of Wash buffer 3 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Place v-Well 96 Well plate F3 under ?lter plate.
Collect fraction 3 in plate F3.
Add 100 pl of Wash buffer 3 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Collect remainder of fraction 3 in plate F3.
Fraction 3 contains the pH 5 eluant.
Add 100 pl of Wash buffer 4 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Place v-Well 96 Well plate F4 under ?lter plate.
Collect fraction 4 in plate F4.
Add 100 pl of Wash buffer 4 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Collect remainder of fraction 4 in plate F4.
Fraction 4 contains the pH 4 eluant.
Add 100 pl of Wash buffer 5 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Place v-Well 96 Well plate F5 under ?lter plate.
Collect fraction 5 in plate F5.
Add 100 pl of Wash buffer 5 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Collect remainder of fraction 5 in plate F5.
Fraction 5 contains the pH 3 eluant.
Add 100 pl of Wash buffer 6 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Place v-Well 96 Well plate F6 under ?lter plate.
Collect fraction 6 in plate F6.
Add 100 pl of Wash buffer 6 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Collect remainder of fraction 6 in plate F6.
Fraction 6 contains the organic solvent eluant.

FreeZe until proceeding With chip binding protocol.
Chip Binding Protocol
Buffer List:

lMAC30 Chip:
40

1. 100 mM Sodium Phosphate+0.5M NaCl pH 7.0.
2. 100 mM CuSO4.
3. 100 mM NaAcetate pH 4.0.

CMl0 Chip:
45

1. 100 mM Sodium Acetate pH 4.0
Material List:

Mix 5 times.

Bioprocessors.

Pipet 50 pl from each Well of sample plate to corresponding
Well in ?lter plate.
50

lMAC30 chips.
CMl0 chips.
Place chips into bioprocessor.
A. Load LMAC Chips With Copper

[This step is included because there is a dead volume When

pipeting With the robot; When the robot pipets to collect
the sample the ?rst time, it Will not collect all the mate
rial. The addition of 50 pl U1 and mixing alloWs the
residual material to be obtained and added to the ?rst 50

ill-1
Vortex 30' at 40

55

E. Collect Fractions

Place v-Well 96 Well plate Fl under ?lter plate.

lMAC3 chip.

Collect ?oW-through in plate Fl.
Add 100 pl of Wash buffer 1 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Collect pH 9 eluant in plate Fl.
Fraction 1 contains the How through and the pH 9 eluant.
Add 100 pl of Wash buffer 2 to each Well of ?lter plate.
Vortex 10' at Room Temperature (RT).
Place v-Well 96 Well plate F2 under ?lter plate.
Collect fraction 2 in plate F2.
Add 100 pl of Wash buffer 2 to each Well of ?lter plate.

Load 50 pl of CuSO4 onto each spot on the EVlAC3 chip.
Centrifuge the bioprocessor at 700 rpm for 1 minutes.
Vortex 5' at Room Temperature (RT).
Remove CuSO4 after Vortex.
Water rinse.
B. NeutraliZe lMAC Chips
Load 50 pl of NaAcetate pH 4.0 onto each spot on the

Vortex 5' at Room Temperature (RT).
60

Remove NaAcetate after Vortex.
Water rinse.

C. Equilibrate Chips
Add 150 pl of appropriate chip binding buffer into each
65

Well.
Centrifuge the bioprocessor at 700 rpm for 1 minutes for
CM10.

Vortex 5' at Room Temperature (RT).
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malignant diseases tend to have the same distribution of peak
intensity. These biomarkers of the present invention can be

Remove buffer.

Add 150 pl of appropriate buffer into each Well.
Vortex 5' at Room Temperature (RT).

used alone, or in conjunction With, other proteins previously

Remove buffer after vortex.

identi?ed to be important biomarkers for ovarian cancer.

D. Bind Fractions to Chips
Add 90 ul of corresponding buffer into each Well.

Example 2

Add 10 ul of Q column fraction.
Centrifuge the bioprocessor at 700 rpm for 1 minutes for

Marker Puri?cation and ID

CM10.

Vortex 60' at Room Temperature (RT).
Remove sample and buffer.
E. Wash Chips
Add 150 pl of corresponding buffer into each Well.
Vortex 5' at Room Temperature (RT).
Remove buffer after vortexing.
Add 150 p. 1 of corresponding buffer into each Well.
Vortex 5' at Room Temperature (RT).
Remove buffer after vortexing.
Add 150 pl of corresponding buffer into each Well.
Vortex 5' at Room Temperature (RT).
Remove buffer after vortexing.

Biomarkers Were puri?ed using combinations of chro
matographic techniques employing a range of Biosepra sor

bents typically folloWed by SDS-PAGE. The puri?cation
schemes Were monitored using a ProteinChip Reader to track

biomarkers of interest. For proteins smaller than 30 kDa,
intact bands of interest Were extracted from gels and reana

20

proteins larger than 30 kDa Were in-gel digested. Tryptic
digests Were analyZed by peptide mapping using the Protein
Chip Reader and by tandem MS using a Q-STAR (Applied

Water rinse 2 times.
F. Add Matrix

Remove bioprocessor top and gasket.

25

Remove the Water from spots With vacuum.

DraW a circle around each spot using a pap pen.
For SPA:
30

biomarkers Were identi?ed using antibodies.

The techniques described in the preceding paragraph

Vortex 5 minutes at RT.

Add 1.0 ul to each spot.
Air dry 10 minutes.
Add 1.0 ul to each spot.

Air dry.
Data Analysis:

Biosystems) instrument ?tted With a PC1-1000 ProteinChip
Interface. Biomarkers smaller than 4 kDa Were enriched by

combinations of chromatographic techniques and identi?ed
directly by tandem MS Without SDS-PAGE puri?cation and/
or trypsin digestion. In some instances (e.g., LysoZyme C) the

AlloW the chips to dry 10 minutes.
Add 400 pl of 50% ACN, 0.5% TFA to SPA tube.

lyZed using the ProteinChip Reader to con?rm their exact
masses matched With the original biomarker. The gel-ex
tracted proteins Were in-solution digested With trypsin and

alloWed the identi?cation of the biomarkers of Table 1

35

Data Were acquired using CiphergenExpress. Mass cali
bration Was performed using external calibrants, intensity

Example 3
Discovery of Biomarkers

normalization Was based on total ion current using an external

normalization factor, and baseline subtraction Was per

40

formed. Peak detection Was performed in CiphergenExpress
using the criteria that a peak must have a signal/noise ratio of
3:1 and be present in 20% of the spectra. Statistical analysis
Was performed in CiphergenExpress using the Mann-Whit
ney test (for tWo groups, e.g., benign versus ovarian cancer) or

malignant, 13 of loW malignant potential, 45 benign) using
the ProteinChip Biomarker System® (Ciphergen Biosys
45

Kruskal-Wallis test (for multiple group comparison, e.g.,
benign ovarian disease versus ovarian cancer versus ovarian

cancer With loW malignant potential (LMP) versus other
50

lioma, a stromal ovarian cancer, etc.

intensity betWeen diagnostic groups Were determined by

A four-Way comparison Was performed using the Kruskal

Kruskal-Wallis test and ROC curve analysis.
55

Results
Over one hundred protein peaks from ovarian cyst ?uid

(also called ovarian cancer With loW malignant potential), and
other malignancies (Which include stromal ovarian tumor,
metastatic disease, and uterine cancer).
The biomarkers for ovarian cancer in ovarian cyst ?uid
identi?ed using the above methods are set forth in Table 1.

lyZed in duplicate on NP20, lMAC30, CM10, H50, and Q10
ProteinChip arrays. Ciphergen Express® softWare Was used
to identify m/ Z peaks and to compare peak intensity betWeen

diagnostic groups. Statistically signi?cant differences in peak

Results/ Conclusions:
Wallis test. The four groups Were benign ovarian disease,
invasive epithelial ovarian cancer, borderline ovarian cancer

tems), a platform for surface-enhanced laser desorption/ion
iZation time-or-?ight mass spectrometry. Ovarian cyst ?uid
Was analyZed unfractionated, and also folloWing anion
exchange fractionation. Aliquots of each fraction Were ana

malignancies (such as malignancies other than invasive epi
thelial ovarian cancer, including metastatic cancer (e.g., gas
tric cancer frequently metastasiZes to the ovary), mesothe

Methods
Protein expression pro?ling Was performed on ovarian cyst
?uids from seventy-four patients With ovarian tumors (16

differed signi?cantly in peak intensity betWeen benign,
60

malignant, and ovarian tumors of loW malignant potential
(see, Tables 2 and 3, beloW). Of these cyst ?uid proteins, the
folloWing have been identi?ed by MS/MS or MS/MS With

Most notably, it has been determined that most peaks of

immunoassay validation: Apolipoprotein C l (m/Z:6520,

signi?cance are similarly up- or doWn-regulated based on the

p:0.0003), ApolipoproteinA ll (m/Z:8690, p:0.00006), and
Apolipoprotein Cll (m/ZI8918, p:0.0002); Calgranulin A
(m/Z:10840, p:0.00001) and Calgranulin C (m/Z:10430,

characteristics of malignancy (or not) of the disease. Benign
disease and ovarian cancer of loW malignant potential (also
called borderline disease) tend to have the same distribution

of peak intensity, While invasive ovarian cancer and other

65

p:0.00004); Transthyretin (doubly charged) (m/Z:6880,
p:0.00005); and Calcyclin (m/Z:10210, p:00002).
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TABLE 3

SELDI-TOF MS analyses of anion exchange fractionated cyst fluids from individual
patients adsorbed to CM10 ProteinChip arrays and read at high laser intensity
have identi?ed thirty-?ve biornarkers that differ betWeen patients With benign
and loW malignant potential turnors versus malignant epithelial ovarian tumors.

M/Z

M/Z Std. Fraction(s) P—value(s)

ROC(s)

2414

3.49

1, 2, 5

0.0085, 0.0085, 0.01263

0.231, 0.269, 0.25

2429
3286
3353

6.46
5.03
3.76

1
5
5

0.00407
0.01091
0.00850

0.212
0.731
0.731

3446

5.08

2, 6

0.01681, 0.00407

0.718, 0.782

3517
3562
4227
4302
4558

5.06
5.86
7.39
13.26
5.85

6
6
5
5
5

0.00365
0.01263
0.00988
0.00034
0.00003

0.782
0.731
0.250
0.854
0.878

4733

6.57

4, 5

0.01604, 0.01459

0.25, 0.269

4958

9.22

5

0.00430

0.250

6395
6443

9.67
22.16

1, 5
1, 4

0.0013, 0.00479
0.02893, 0.00027

0.814, 0.737
0.66, 0.827

6507
6604
7136
7535
7910
8100
8331
8554

8.8
6.02
14.81
2.57
4.71
21.18
19.94
14.59

6
1
1
4
4
1
1
1

0.00035
0.00075
0.00505
0.00003
0.00003
0.01391
0.01845
0.00767

0.814
0.782
0.744
0.878
0.897
0.731
0.692
0.737

10836

9.21

11733
12693
13130
13273
13291
13891

4.89
7.59
18.92
8.49
18.99
13.07

2, 4

0.02535, 0.03741

0.699, 0.667

3
1
1
1
2
4

0.00592
0.01038
0.04417
0.0043
0.03437
0.00003

0.288
0.718
0.673
0.756
0.699
0.891

15082

27.66

3

0.00186

0.75

15127
15212
15335

20.16
31.3
21.31

5
6
4

0.00208
0.00155
0.00003

0.788
0.788
0.878

15878

23.46

3, 4, 5, 6

0.00345, 0.00002, 0.0001, 0.00004 0.801, 0.897, 0.854, 0.865

15987

15.01

3 4

0.00175, 0.00002

0.807, 0.878

Kruskal-Wallis P-value(s) and AUC values from ROC analyses are shown.
AUC values < 0.5 indicate that “peak intensity” Was decreased in the ovarian cancer cases.

TABLE 4
SELDI-TOF MS analyses of anion exchange fractionated cyst fluids from individual
patients adsorbed to CM10 ProteinChip arrays and read at lOW laser intensity have
identi?ed twenty-eight biornarkers that differ betWeen patients With benign and
lOW malignant potential tumors versus malignant epithelial ovarian tumors.

M/Z

M/Z Std. Fraction(s) P—value(s)

ROC(s)

3368

2.9

6

5.00E-05

0.865

3377
3439
3487

3.21
3.22
2.52

1, 5
1, 5, 6
5, 6

0.0231, 0.01761
0.01681, 0.01932, 0.00196
0.00175, 0.00261

0.699, 0.699
0.718, 0.698, 0.788
0.769, 0.788

4349
4626

4.11
2.27

5
5

0.03901
0.00002

0.679
0.878

6431

5.35

6461
6496
6643
6830
6926
7566
7654

7.72
5.51
5.91
9.37
5.7
2.76
13.53

1, 4, 5, 6

0.00005, 0.00008, 0.00155, 0.00196

0.891, 0.846, 0.769, 0.56

1
1
1
1
6
4
1

0.00185
0.00261
0.00004
0.01681
0.00001
0.00002
0.00505

0.794
0.775
0.858
0.698
0.923
0.878
0.737

7936

4.89

3, 4

0.00075, 0.00002

0.8, 0.897

8134
8577
9117

5.69
9.55
3.52

1
1
2

0.00479
0.00479
0.0085

0.75
0.737
0.288

10847

13.11

1, 2, 3, 4

0.00006, 0.02769, 0.03586, 0.02023

0.884, 0.66, 0.66, 0.724

12711
13279
13887

8
17.93
14.8

1
1
4

0.01391
0.00233
0.00004

0.72
0.77
0.891

15140

20.99

3, 4, 5, 6

0.00327, 0.000004, 0.0043, 0.00011

0.75, 0.897, 0.75, 0.846

